Adverse Events (AD1)

Adverse event onset date (AEDATE): Event number (AESE QNUM):	
This adverse event has been closed by the Medical Reviewer and may no longer be updated.	
For the purposes of this protocol, Grade 1 (mild) unrelated adverse events should not be reported in AdvantageEDC.	
1. Adverse event name: (A1DESCPT)	
2. Advers e event name: (A1 SPINAE)	Respiratory depression-Respiratory depression Alcohol intoxication-Alcohol intoxication Hepatic impairment-Hepatic impairment Drug withdrawal syndrome-Drug withdrawal syndrome (from abrupt discontinuation of suboxone) Depressed level of consciousness-Depressed level of consciousness Hypersensitivity-Hypersensitivity Oral reaction to Suboxone film-Oral reaction to Suboxone film Peripheral edema-Peripheral edema Increased intracranial pressure-Increased intracranial pressure Unintentional pediatric exposure-Unintentional pediatric exposure 99-Other
If "Other", specify:(A1DESCPT)	
3. Date site became aware of the event: (A1A WA RDT)	(mm/dd/yyyy)
4. Severity of event:(A1 SEVRTY)	1-Grade 1 - Mild 2-Grade 2 - Moderate 3-Grade 3 - Severe
5. Is there a reasonable possibility that the extended-release naltrexone caused the event?(A1RDRUG1)	No Yes
If "Yes", action taken with extended-release nalifexone:(A1ADRUG1)	O-None 1-Decreased drug 2-Increased drug 3-Temporarily stopped drug 4-Permanentity stopped drug
6. Is there a reasonable possibility that BUP-NX (Suboxone) caused the event?(A1RDRUG2)	□ No □ Yes
If "Yes", action taken with buprenorphine:(A1ADRUG2)	O-None 1-Decreased drug 2-Increased drug 3-Temporarily stopped drug 4-Permanently stopped drug
7. If "Unrelated" to the study drug(s), alternative etiology: <i>∖A1ALTESD)</i>	O-None apparent 1-Study disease 2-Concomitant medication 3-Other pre-existing disease or condition 4-Accident, trauma, or external factors *Additional Options Listed Below
If "Other," specify:(A1AEPSP)	
8. Outcome of event (A1 OUTCM)	1-Ongoing 2-Resolved without sequelae 3-Resolved with sequelae 4-Resolved by convention 5-Death
9. Date of resolution or medically stable:(A IRESDT)	(mm/dd/yyyy)

Except for "None of the following", all selections in the question below will designate this as a Serious Adverse Event (SAE). The Serious Adverse Event Summary (AD2) form should be completed for all Serious Adverse Events reported.

Web Version: 1.0; 5.00; 09-19-16

10. Was this event associated with: (A1A SSOC) a. If "Death", date of death: (A1D THDT)	O-None of the following 1-Death 2-Life-threatening event 3-Inpatient admission to hospital or prolongation of existing hospitalization 4-Persistent or significant incapacity 5-Congenital anomaly or birth defect 6-Important medical event that required intervention to prevent any of the above 7-Seizure 8-Hospitalization for a medical event	
	(mm/dd/yyyy)	
b. If "In patient admission to hospital or prolongation of hospitalization":		
Date of hospital admis sion: (A1HOSPAD)	(mm/dd/yyyy)	
Date of hospital discharge: (A1HOSPDC)	(mm/dd/yyyy)	
Comments: (AD 1C OMM)		

Additional Selection Options for AD1

Event number (AESEQNUM) (key field): 01-1st Adverse Event of the day 02-2rd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 05-5th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 08-8th Adverse Event of the day 10-9th Adverse Event of the day

If "Unrelated" to the study drug(s), a her native etiology: 5-Concurrent illnes scondition (not pre-exising) 6-Study procedures 7-Naloxone challenge 99-Other

		Seri	ous Adverse Event Summary (AD2)
erse event onset date (AEDATE): Event number (AESE QNUM):			Web Version: 1.0; 1.00;
This adverse event has been closed by the Medical	Reviewer and may no longer be updated.		
Initial narrative description of serious adverse event:			
(A2 SUM M.)			
Relevant past medical history: (A2 SAEM HX) No	Yes Unknown		
Allergies, pregnancy, smoking and alcohol use, hyperte.	nsion, diabetes, epile psy, depression, etc.		
(A2 MED HX)			
	5 5		
Medications at the time of the event: (A2 SAEMED) 1 Medication (Generic Name)	lo Yes Unknown Indication		
(A2_01DNM)	(A2_01DIN)		
(A2_02DNM)	(A2_02DIN)		
(A2_03DNM)	(A2_03DIN)		
(A2_04DNM)	(A2_04DIN)		
(A2_05DNM)	(A2_05DIN)		
(A2_06DNM)	(A2_06DIN)		
(A2_07DNM)	(A2_07DIN)		
(A2_08DNM)	(A2_08DIN)		
(A2_09DNM)	(A2_09DIN)		
(A2_10DNM)	(A2_10DIN)		
Treatments for the event: (A2 SAETRT) \(\bigcap \) No \(\bigcap \) Ye	s Unknown		
Treatment	Indication	Date Treated (mm/dd/yyyy)	
(A2_1 TNME)	(A2_1 TIND)	(A2_1LTDT)	
(A2_2 TNME)	(A2_2 TIND)	(A2_2LTDT)	
(A2_3TNME)	(A2_3TIND)	(A2_3LTDT)	
(A2_4TNME)	(A2_4TIND)	(A2_4LTDT)	
(A2_5TNME)	(A2_5TIND)	(A2_5LTDT)	

 $5\cdot$ Labs/tests performed in conjunction with this event: (A2SAELAB) \square No \square Yes \square Unknown

Lab/Test	Findings	Date of Test (mm/dd/yyyy)
(A2_1LBNM)	(A2_1LBIN)	(A2_1LBDT)
(A2_2LBNM)	(A2_2LBIN)	(A2_2LBDT)
(A2_3LBNM)	(A2_3LBIN)	(A2_3LBDT)
(A2_4LBNM)	(A2_4LBIN)	(A2_4LBDT)

(A2_5LBNM)	0	(A2_5LBIN)		(A2_5LBDT)
Follow :=:				
i. Follow-up: Include labs/te	est results as they become available, clinical	changes, consultant diagnosis	sis, etc.	
(A2 FOL LUP)	yl			
. Additional infor	rmation requested by the Medical Monitor:			
	The transfer of the second sec		_	
(A2 ADD INF)				
Have all M	Medical Monitor requests been addressed? (A2)	PR QADDR)		Yes

Additional Selection Options for AD2 Event number (AESEQNUM) (key field): 01-1st Adverse Event of the day 02-2rd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 05-5th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 08-8th Adverse Event of the day 10-9th Adverse Event of the day

MID A	Clini	riale	NIO	work

Serious Adverse Event Medical Reviewer (AD3) Web Version: 1.0; 3.00; 08-19-14 Adverse event onset date (A EDA TE): Event number (AESE QNUM): 1. Was this determined to be a serious adverse event?(A 3SAE) □ No □ Yes 2. Was this event considered associated with extended-release naltrexone?(A3RXRNTX) □ No □ Yes 3. Was this event considered associated with buprenorphine? (A3RELDRG) □ No □ Yes 4. Was this event expected? (A3EXPECT) □ No □ Yes 5. Is this a standard expedited/reportable event? □ No □ Yes (i.e., is it serious, unexpected and related to the rapy)(A3EXPFDA) If "No", is this an expedited/reportable event for other reasons?(A 3EXP OTH) □ No □ Yes 6. Does the protocol need to be modified based on this event?(A3MPROT) □ No □ Yes 7. Does the consent form need to be modified based on this event? (A3MCNST) □ No □ Yes 8. Is the review complete? (A3REVDNE) □ No □ Yes If "No", what additional information is required: (A3ADDINF) As sessed by:(A 3ASRID) Reviewed by: (A3REVID) (intials) Comments: (A3COMM)

Additional Selection Options for AD3 Event number (AESEQNUM) (key field): 01-1st Adverse Event of the day 02-2rd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 05-5th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 08-8th Adverse Event of the day 10-9th Adverse Event of the day

CTN-ASI Lite v1.0: Drug/Alcohol Use (ASD)

Segment (PROTSEG): B Visit number (VIS NO):

CTN-ASI Lite v. 1 Follow-Up: Drug/Alcohol Use

Route of Administration:

1 = Oral 2 = Nasal 3 = Smoking 4 = Non-IV injection 5 = IV injection

Note the **usual or most recent route**. For more than one route, choose the most severe. The routes are listed from least severe to most severe. If Past 30 Days is zero, route

should	40	"No f	0.00	linn	blo"

Substance	A Past 30 (Days)	D Route of Administration	Comments
D1 Alcohol (any use at all):	(ADALA30D) (xx)	-	(ADALA COM)
D2 Alcohol (to intoxication):	(ADALBOD) (xx)	-	(ADALICOM)
D3 Heroin	(ADHER30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) S moking 4-(4) Non IV injection 5-(5) IV injection 96-(95) Not applicable 97-(97) Not answered	(ADHERCOM)
D4 Methadone/LAAM (prescribed):	(ADMDP30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADMDPCOM)
D4a Methadone/LAAM (#icit):	(ADMDI30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADMDICOM)
D5 Other Opiates/Analgesics:	(ADOPI30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADOPICOM)
D6 Barbiturates:	(ADBAR30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) S moking 4-(4) Non IV injection 5-(5) IV injection 96-(95) Not applicable 97-(97) Not answered	(ADBARCOM)

Web Version: 1.0; 2.00; 03-10-14

D7 Other Sedatives/ Hypnotics/Tranquilizers:	(ADSHT30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) S moking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADSHTCOM)
D8 Cocaine:	(AD COC 30 D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) 5 moking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADCOCCOM)
D9 Amphetamines:	(ADAMP30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) 5 moking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADAMPCOM)
D9 a Methamphetamine:	(ADMET30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADMETCOM)
D10 Cannabis:	(AD THC 30 D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADTHCCOM)
D11 Hallucinogens:	(ADHAL30D) (ox)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADHALCOM)
D12 Inhalants:	(ADINH30D) (xx)	1-(1) Oral 2-(2) Nasal 3-(3) Smoking 4-(4) Non IV injection 5-(5) IV injection 96-(96) Not applicable 97-(97) Not answered	(ADINHCOM)
D36 Nicotine:	(ADNIC30D) (xx)		
D13 More than 1 substance per day (including alcohol, excluding nicotine):	(ADGT130D) (xx)	-	(ADGT1COM)

D14 Currently, which substance is the major problem?

Interviewer's hould determine the major drug or drugs of abuse (excluding Nicotine use). Code the number next to the drug in 01-12 (code prescribed or illicit methadone as 04), 00 = no problem, 15 = alcohol and one or more drugs; 16 = more than one drug but no alcohol. Ask participant when not clear.

0-00 - No problem 1-01 - Alcohol (any use at all)	
2-02 - Alcohol (to intoxication) 3-03 - Heroin	
4-04 - Methadone/LAAM (prescribed or illicit)	
5-05 - Other Opiates/Analgesics 6-06 - Barbiturates	
7-07 - Other Sedatives/Hypnotics/Tranquilizers 8-08 - Cocaine	
9-09 - Amphetamines 9a-09a - Methamphetamine	
10-10 - Cannabis	
11-11 - Hallucinogens 12-12 - Inhalants	
15-15 - Alcohol and one or more drugs 16-16 - More than one drug, but no alcohol	
(ADMAJ DRG)	
OR	
(ADMJDGNA) (97) Not answered	
Comments: (ADM JDGC M)	
D17 How many times since your last ASI have you had Alcohol DTs?	
	decrease in alcohol in take. Characterized by shaking, severe discrientation, fever, hallucinations; they usually require medical attention.
(ADALCDT) (xx)	
(ADALCDT) (xx) OR	
(ADALDTNA) (97) Not answered	
(2.2) [(-),	
Comments:(ADALDTCM)	
How many times since your last ASI have you been treated for:	
Include de bxification, halfway houses, in/outpatient counseling and AA or NA (if 3+ meeti	ings within one month period).
D19 Alcohol abuse:	
(ADALCTRT) (xx)	
OR	
(ADATRTNA) (97) Not answered	
Comments:(ADATRTCM)	
D20 Drug abuse:	
(ADDRGTRT) (xx)	
OR	
(ADDTRTNA) (97) Notanswered	
Comments:(ADDTRTCM)	
How many of these were detox only:	
D21 Alcohol:	
• If D19 = 00, then question D21 is Not applicable.	
(ADADE TOX) (xx)	
OR	
(ADADTXNA) (96) Not applicable (97) Not answered	
Comments:(ADADTX CM)	

D22 Drugs:
• If D2 0 = 00, then question D22 is Not applicable.
(ADDDETOX) (xx)
OR
(ADDDTXNA) (96) Not applicable (97) Not answered
Comments:(ADDDTXCM)
How much money would you say you spent during the past 30 days on: Max. = \$99999
D23 Alcohol:
Only count actual money spent. What is the financial burden caused by a loohol?
(ADALCMNY) \$ (xxxxxx)
OR .
(ADAMNYNA) (97) Not answered
Comments: (ADAM NYCM)
D24 Drugs:
Only count actual money spent. What is the financial burden caused by drugs?
(ADDRGMNY) \$ (xxxxx)
OR .
(ADDMNYNA) [(97) Not answered
Comments:(ADDMNYCM)
D25 How many days have you been treated in an outpatient setting for alcohol or drugs in the past 30 days?
• Include AA/NA
(ADOUTPAT) (xx) days
OR .
(AD OPTNA) (97) Not answere d
Comments:(ADOPTCOM)
D26 How many days in the past 30 have you experienced alcohol problems?
• Include: Craving, withdrawal symptoms, disturbing effects of use, or wanting to stop and being unable to.
(ADAP30D) (xx) days
OR
(ADAP30NA) (97) Not answered
Comments:(ADAP30CM)
For questions D28-D31, please ask participant to use the Participant Rating Scale. The participant is rating the need for additional substance abuse treatment.
D28 How troubled or bothered have you been in the past 30 days by these alcohol problems?

0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely	
OR	
(ADAB30NA) (97) Not answered	
Comments:(ADAB30CM)	
D30 How important to you now is treatment for these alcohol problems?	
0(0) Not at all 1(1) Slightly 2(2) Moderately 3(3) Considerably 4(4) Extremely	
OR	
(ADAI30NA) (97) Not answered	
Comments:(ADAI30CM)	
D27 How many days in the past 30 have you experienced drug problems?	
 Include: Craving, with drawal symptoms, disturbing effects of use, or wanting to stop and being 	g unable to.
(ADDP30D) (xx) days	
OR	
(ADDP30NA) (97) Not answered	
(a) heraidised	-
Comments:(ADDP 30 CM)	
D29 How troubled or bothered have you been in the past 30 days by these drug problems?	
0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely	
OR	
(ADDB30NA) (97) Not answered	
Comments:(ADDB 30 CM)	
D31 How important to you now is treatment for these drug problems?	
0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely	
OR (ADD/30/NA)	
(91) NO. allowelled	
Comments:(ADD/30CM)	
Confidence Ratings: Is the above information significantly distorted by:	

D34 Participants misrepresentation?		
(ADMISREP) (0) No (1) Yes		
(I) Issued to the control of the con		
DOT DOTAGE AND THE PROPERTY OF		
D35 Participants inability to understand?		
(ADUNDRST) (0) No (1) Yes		
Commerts: (ASD COM M)		

CTN-ASI Lite v1.0: Employment/Support Status (ASE) Web Version: 1.0; 1.00; 12-17-13 Segment (PROTSEG): B Visit number (VIS NO): CTN-ASI Lite v. 1 Follow-Up: Employment/Support Status E1 Education completed since your last ASI: GED = 12 years
Include formal education only. (AE EDC PYR) (AE EDC PMT) (xx) b. months (AE EDC PNA) [(97) Not an swe red Comments:(A EEDCPCM) E2 Training or technical education completed since your last ASI: Formal/organized training only. For military training, only include training that can be used in civilian life, i.e., electronics or computers. (AETECPMT) (xx) months (AETECPNA) [(97) Not answered Comments:(AETECPCM) E4 Do you have a valid driver's license? Valid license; not suspended/revoked. 0-(0) No 1-(1) Yes 97-(97) Not answered (AE DR VLSC) Comments:(A EDR VLCM) E5 Do you have an automobile available? • If answer to E4 is "No", then E5 must be "No". Does not require ownership, only requires availability on a regular basis. 0-(0) No 1-(1) Yes 97-(97) Not answered Comments:(A EAUTOCM)

E7 Usual (or last) occupation since your last ASI?

 Us e Hollingshead Categories Reference Sheet. 	
1-(1) Higher Executive, Major Professionals, Owner of Large Business	
2-(2) Business Manager, Owner (medium sized business), Other Professional 3-(3) Administrative Personnel, Manager, Owner/Proprietor of Small Business	
4-(4) Clerical and Sales, Technician, Owner of Small Business	
5-(5) Skilled Manual - usually having had training	
6-(6) Semi-skilled 7-(7) Unskilled/Unemployed	
8-(8) Homemaker	
9-(9) Student/No Occupation/Disabled (AE OCCUPT)	
Specify:	
(AE OCCP SP)	
OR	
(AE OCCPNA) (97) Not answered	
Comments:(AEOCCPCM)	
E9 Doessomeone contribute the majority of your support?	
 Is participant receiving any regular support (i.e., cash, food, housing) from familly/friend? Include spouse's contribution; exclude support by an institution. 	
0-(0) No	
1-(1) Yes 96-(96) Not applicable	
97-(97) Not answered	
(AE SUPP RT)	
Comments:(A ESUP PCM)	
E11 How many days were you paid for working in the past 30 days?	
Include "under the table" work, paid sick days, and vacation.	
(45040)	
(AEPAID) (xx) days	
OR	
(AEPAIDNA) (97) Not answered	
Comments:(AEPA IDCM)	
For questions E12-E17: How much money did you receive from the following sources in the past 30	days?
Max. = \$99999	
E12 Employment (net income):	
Net or "take home" pay, include any "under the table" money.	
(AEEM PMNY) \$ (xx xxxx)	
OR	
(AEEMNYNA) (97) Not answere d	
Comments:(AEEMNYCM)	
F42 the major manufacture of the same and th	
E13 Unemployment compensation:	
(AEUNEMNY) \$ (xxxxxx)	
OR	
(AEUMN YNA) (97) Not ans wered	

E14 Welfare: • Include food slamps, transportation money provided by an agency to go to and from treatment. (AEWLFMNY) \$ (\location \text{(\location on the agency to go to and from treatment.)} OR (AEWMNYNA) (97) Not answered Comments: (AEWMNYCM)
E15 Pensions, benefits, or Social Security: • Include disability, pensions, retirement, veterar/s benefits, SSI & workers' compensation. (AEPENMNY) \$ (xxxxxx) OR (AEPMNYNA) (97) Not answered Comments: (AEPMNYCM)
Mate, family or friends: • Maney for personal expenses, (i.e., clothing), include unreliable sources of income (e.g., gambling). Record cash payments only, include windfalls (unexpected), money from loans, gambling, inheritance, tax returns, etc. (AEMATMNY) \$ (xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Cash obtained from drug dealing, stealing, fencing stolen goods, gambling, prostitution, etc. Donot attempt b convert drugs exchanged to a dollar value. (AEILL MNY) \$ (xxxx) OR (AEIMNYNA) (S7) Not answered Comments:(AEIMNYCM)
E18 How many people depend on you for the majority of their food, shelter, etc.? • Must be regularly depending on participant; do include alimonylchild support; do not include the participant or self-supporting spouse, etc. (AEDEPEND) (xx) max = 99 OR (AEDPNDNA) (97) Not answered Comments: (AEDPNDCM) E19 How many days have you experienced employment problems in the past 30 days?

- Include inability to find work, if they are actively looking for work, or problems with present job in which that job is jeopardized.
- If the participant has not had the opportunity to work, due to incarceration or other controlled environment, the appropriate answer to E19 is NA and the participant rating in E20 should also be NA as it depends on the problem day question.

(AEEP30D) (xx) days
OR (AEEP30NA) [96] Not applicable [97] Not ans wered
PLEE SOLVY — (CV) ALL ADMINISTRATION — (CV) ADMI
(AEEP30CM)
For questions E20-E21: Please ask participant to use the Participant Rating Scale. The participants ratings in questions E20 and E21 refer to question E 19. Stress help in finding or preparing for a job, not giving them a job.
E20 How troubled or bothered have you been by these employment problems in the past 30 days? • If the participant has been incarcerated or detained during the past 30 days, they cannot have employment problems. O-(0) Not at all
1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely
OR
(AEEB30NA) (96) Not applicable (97) Not ans we red
Comments:(AEEB30CM)
E21 How important to you now is courseling for these employment problems?
0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely
(AEECBOD) COR
(AEEC30NA) (97) Not answered
Commertis: (AEEC30CM)
Confidence Ratings: Is the above information significantly distorted by:
E23 Partic pant's misre presentation?
(AEMISREP) (0)No (1) Yes
E24 Participant's inability to understand?
(AEUNDRST) (0) No (1) Yes
Comments: (ASEC OMM)

CTN-ASI Lite v1.0: Family/Social Relationships (ASF) Web Version: 1.0; 1.00; 12-18-13 Segment (PROTSEG): B Visit number (VIS NO): CTN-ASI Lite v. 1 Follow-Up: Family/Social Relationships F1 Marital status: Common-law marriage = 1: Specify in Comments. 1-(1) Married 2-(2) Remarried 3-(3) Widowed 4-(4) Separated 5-(5) Divorced (AFMRTLST) 97-(97) Not answered Comments:(AFMRTLCM) F3 Are you satisfied with this situation? Satisfied = Generally liking the situation. Refers to question F1. 0-(0) No 1-(1) Indifferent 2-(2) Yes 97-(97) Not answered (AFMS SAT) Comments:(AFMSATCM) F4 Usual living arrangements (since your last ASI): 1-(1) With sexual partner and children 2-(2) With sexual partner alone 3-(3) With children alone 4-(4) With parents 5-(5) With family 6-(6) With friends 7-(7) Alone 8-(8) Controlled environment 9-(9) No stable arrangements 97-(97) Not answered (AFLIVARR) Comments: (AFL VARCM) F6 Are you satisfied with these arrangements? Refers to response in question F4. 1-(1) Indifferent 2-(2) Yes 97-(97) Not answered

Comments:(AFLSATCM)			
Do you live with anyone who:			
F7 Has a current alcohol problem? C-(0) No 1-(1) Yes 97-(97) Not answered Comments:(AFLIVALCM)			
G-(0) No 1-(1) Yes 97-(97) Not answered Comments:(AFLVDGCM)			
F9 With whom do you spend most of your free time? • If a girlfriend/boy/riend is considered as family by participant, then they must refer to the 1-(1) Family 2-(2) Friends 3-(3) Alone 98-(97) Not answered	om as family throughout this section, not as a frie	d. Familly is not to be referred to as "friend."	
Comments:(AFFREECM)			
P10 Are you satisfied with spending your fee time this way? • A satisfied response must indicate that the person generally likes the situation. Refers O-(0) No 1-(1) Indifferent 2-(2) Yes 97-(97) Not answered Comments:(AFSFRECM)	to question F9.		
Have you had significant periods in which you have experienced serious problems getting alk • "Serious problems" mean those that endangered the relationship. • A "problem" requires contact of some sort, either by telephone or in person. Indicate "Note"			
F18 Mother:	A Past 30 Days 0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered		
F19 Father:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered		

F20 B rothers/sisters:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
F21 Sexual partner/s pouse:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered (AFSPS300)
F22 Children:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
F23 Other significant family (specify): (AFOSFMSP)	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
F24 Close friends:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
F25 Neighbors:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
F26 Co-wor kers:	0-(0) No 1-(1) Yes 96-(96) Not applicable 97-(97) Not answered
Did anyone abuse you? (F18-F26)	A Past 30 Days
F28 Physically (caused you physical harm)?	0-(0) No 1-(1) Yes 97-(97) Not answered
F29 S exually (forced sexual advances/acts)?	0-(0) No 1-(1) Yes 97-(97) Not answered
Comments:(AFPRBLCM)	
F30 How many days in the past 30 have you had serious conflicts with your family?	
(AFFMC30D) (xx) days	
(AFFC30NA) (97) Not answered	
Comments:(AFFC30CM)	
For questions F32 and F34, please ask participant to use the Participant Rating Scale.	
F32 How troubled or bothered have you been in the past 30 days by these family problems?	
0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely	

OR
(AFFB30NA) (97) Not answered
Comments:(AFFB 30CM)
F34 How important to you now is treatment or counseling for these family problems? Participant is rating his/her need for counseling for family problems, not whether the family would be willing to attend.
0- (0) Not at all 1- (1) Slighty 2- (2) Moderately 3- (3) Considerably 4- (4) Extremely
(AFFI30/NA) (97) Not answered
Comments(AFR30CM)
How many days in the past 30 have you had serious conflicts with other people (excluding family)? (AFSCC30D) (xx) days OR
(AFSC:30NA) (97) Not answered
Comments:(AFSC30CM)
For questions F33 and F35, please ask participant to use the Participant Rating Scale.
F33 How troubled or bothered have you been in the past 30 days by these social problems?
0-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely
(AFSB 30NA) (97) Not answered
Comments:(AFSB30CM)
F35 How important to you now is treatment or counseling for these social problems?
• Include participant's need to seek treatment for such social problems as lone liness, inability to socialize, and dissatisfaction with friends. Participant rating should refer to dissatisfaction, conflicts, or other serious problems. Exclude problems that would be eliminated if participant had no substance abuse.
O-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely OR
(AFS/30NA) (97) Not answered
Comments:(AFSB0CM)
Confidence Ratings: Is the above information significantly distorted by:
F37 Participant's misrepresentation?
(AFMISREP) (0) No (1) Yes

F38 Participant's inability to understand?	
(AFUNDRST) (0)No (1) Yes	
Comments:(ASFCOMM)	

	CTN-ASI Lite v1.0: General Information (ASG)	
egment (PROTSEO): B		Web Version: 1.0; 1.00; 01-08-1
sit number (V.S.NO):		
CTN-ASI Lite v. 1 Follow-Up: General Information		
G9 Contactcode:		
1-(1) In person 2-(2) Telephone (Intake ASI must be in person) 3-(3) Mail 97-(97) Not Answered		
G12 Special:		
1-(1) Participant terminated 2-(2) Participant refused 3-(3) Participant unable to respond 96-(96) Not Applicable		
(A GS PUAL)		
G19 Have you been in a controlled environment in the past 30 days? (A place, theoretically, without access to 1-(1) No 2-(2) Jail 3-(3) Alcohol or drug treatment 4-(4) Medical treatment 5-(5) Psychiatric treatment 99-(6) Other 97-(97) Not answered Other (specify):(AGCENVSP) Comments: (AGCENVCM)	drugs/alcohol)	
G19 Have you been in a controlled environment in the past 30 days? (A place, theoretically, without access to 2-(2) Jail 3-(3) Alcohol or drug treatment 4-(4) Medical treatment 5-(5) Psychiatric treatment 99-(6) Other 97-(97) Not answered (A GCNTENV) Other (specify):(A GCENVSP) Comments: (AGCENVCM)	drugs/alcohol)	
G19 Have you been in a controlled environment in the past 30 days? (A place, theoretically, without access to 2-(2) Jail 3-(3) Alcohol or drug treatment 4-(4) Medical treatment 5-(5) Psychiatric treatment 99-(6) Other 97-(97) Not answered Other (specify):(A GCENVSP) Comments: (AGCENVCM) G20 How many days? (Refers to total number of days detained in the past 30 days) • Not applicable if question G19 is "No." (AGCEDAYS) (xx) days OR	drugs/alcohol)	
G19 Have you been in a controlled environment in the past 30 days? (A place, theoretically, without access to 2/2) Jail 3-(3) Alcohol or drug treatment 4-(4) Medical treatment 5-(5) Psychiatric treatment 99-(6) Other 97-(97) Not answered Other (specify):(AGCENVSP) Comments: (AGCENVCM) G20 How many days? (Refers to total number of days detained in the past 30 days) • Not applicable if question G19 is "No." (AGCEDAYS) (xx) days	drugs/alcohol)	

MID A		NIO	hwork

	NIDA CIINICAI Triais Network		
	CTN ASI-Lite v1.0 (ASI)		
Segment (PROTSEG): B		Web	b Version: 1.0; 1.00; 12-17
/isit number (V.S.NO):			
CTN-ASI Lite v. 1 Follow-Up			
Date of assessment (ASIA SMDT)	(mm/dd/yyyy)		
	(пти ослу ууу)		
Date of birth (ASBRTHDT)	(mm/dd/y yyyy)		
Introducing the CT N-ASI Lite v. 1 Follow-Up			
Seven potential problem areas: Medical, Employment/Support Status, Alcohol, Drug, Legal, Family/Social, and Psychological. All clients receive this same standard interview. All information gathered is confidential.			
There are two time periods we will discuss:			
1. The past 30 days 2. Lifetime Data			
Participant Rating Scale: Participant input is important. For each area, I will ask you to use this			
scale to let me know how bothered you have been by any problems in each section. I will also ask you how important treatment is for you for the area being discussed.			Key: Participant Ratin Scale
Please refer to the Participant Rating Scale in the adjacent key.			0=Notatall
If you are uncomfortable giving an answer, then don't answer. Please do not give inaccurate information!			1=Slightly
			2=Mode rately
			3=C onside rably
			4=Extremely
Interviewer Instructions			
1. Leave no blanks			
 Leave no blanks. Make plenty of comments (if another person reads this ASI, they should have a relatively complete picture of the client's perceptions of 	his/herproblems).		
3. Throughout the ASI, please note if not answered or not applicable in the appropriate box.			
4. Terminate interview if client misre presents two or more sections. 5. When noting comments, please write the question number.			
HALF TIME RULE: If a question asks the number of months, round up periods of 14 days or more to 1 month.			
Round up 6 months or more to 1 year.			
CONFIDENCE RATINGS:			
Last two items in each section.			
Do not over interpret. Denial does not warrant misrepresentation.			
Misrepresentation = overt contradiction in information.			
Probe and make plenty of comments!			
CTN-ASI Lite v. 1: Hollingshead Categories			
1 = Higher Executive, Major Professionals, Owner of Large Business 2 = Business Manager, Owner (medium sized business), Other Professional (nurse, optician, pharmacist, social worker, teacher)			
3 = Administrative Personnel, Manager, Owner/Proprietor of Small Business (bakery, car dealership, engraving business, plumbing			
4 = Clerical and Sales, Technician, Owner of Small Business (bank teller, bookkeeper, clerk, draftsman, timekeeper, secretary, carsai 5 = Skilled Manual - usually having had training (baker, barber, brakeman, chef, electrician, fireman, lineman, machinist, mechanic, pa			
6 = Semi-skilled (hospital aide, painter, bartender, bus driver, cutter, cook, drill press, garage guard, checker, waiter, spot welder, machin			

8 = Homemaker 9 = Student/No Occupation/Disabled

7 = Unskilled (attendant, janitor, construction help, unspecified labor, porter). Include Unemployed.

List of Commonly Used Drugs

Alcohol: Beer, wine, liquor

Methadone: Dolophine, LAAM

Opiates: Pain killers = Morphine, Diluaudid, Demerol, Percocet, Darvon, Talwin, Codeine, Tylenol 2, 3, 4 Syrups = Robitussin, Fentanyl

Barbiturates: Nemb utal, Seconal, Tuinol, Amytal, Pentob arbital, Secobarbital, Phenobarbital, Florinol

Sed'Hyp/Tranq: Benzodiazepines = Valium, Librium, Ativan, Serax, Tranxene, Dalmane, Halcion, Xanax, Miltown, Other = Chloral Hydrate (Noctex), Quaaludes

Cocaine: Cocaine Crystal, Free-Base Cocaine or "Crack", and "Rock Cocaine"

Cannabis: Speed, ice, Crystar

Hallucino gens: LSD (Acid), Mes caline, Mushrooms (Psilocybin), Peyote, Green, PCP (Phencyclidine), Angel Dust, Ecstacy

Inhalants: Nitrous Oxide, Amyl Nitrate (Whippits, Poppers), Glue, Solvents, Gasoline, Toluene, etc.

Just note if these are used: Antide pressants,

Ulcer Meds = Zantac, Tagamet Asthma Meds = Ventoline Inhaler, Theodur Other meds = Antip sychotics, Lithium

Alcohol/Drug Section Instructions

The following questions look at two time periods: the past 30 days and lifetime. Lifetime refers to the time prior to the last 30 days. However, if the client has been incarcerated for more than 1 year, you would only gather lifetime information, unless the client admits to significant alcohol/drug use during incarceration. This guideline only applies to the Alcohol/Drug Section.

30 day questions only require the number of days used.

Lifetime use is asked to determine extended periods of use.

Regular use = 3+ times per week, binges, or problematic irregular use in which normal activities are compromised.

Alcohol to intoxication does not necessarily mean "drunk;" use the words "felt the effects," "got a buzz," "high," etc., instead of intoxication. As a rule of thumb, 3+ drinks in one setting, or within a brief period of time, or 5+ drinks in one day defines "intoxication."

How to ask these questions:

"How many days in the past 30 have you used....?"

"How many years in your life have you regularly used...?"

Comments: (ASIC OM M)

CTN-ASI Lite v1.0: Legal Status (ASL) Web Version: 1.0; 1.00; 12-18-13 Segment (PROTSEG): B Visit number (VIS NO): CTN-ASI Lite v. 1 Follow-Up: Legal Status L2 Are you on parole or probation? Note duration and level in comments. 0-(0) No, neither 1-(1) Yes, parole or post release supervision 2-(2) Yes, probation or pre-sentencing diversion 97-(97) Not answered (ALP ROBAT) Comments: (ALPRBTCM) How many times since your last ASI have you been arrested and charged with the following:
Include total numbers of counts, not just convictions. Do not include juvenile [under age 18] crimes, unless they were charged as an adult. Include formal charges only. Comments: L3 Shoplifting/vandalism: OR (ALSLFTNA) (97) Not answered (ALSHPLFT) (ALSLFTCM) OR (ALPPVLNA) (97) Not answered L4 Paro le /probation violations: (ALPP VIOL) (ALPP VLCM) L5 Drug Charges: OR (ALDCHRNA) [(97) Not an swered (ALDRGCHR) (ALD CHRCM) L6 Forgery: (ALFORGER) OR (ALFORGNA) [(97) Not an swered (ALFORGCM) L7 Weapons offense: (ALWEAP ON) OR (ALWEAP NA) [(97) Not answered (ALWEAPCM) L8 Burglary/larceny/B&E: (ALBURGLR) OR (ALBURGNA) [(97) Not answered (ALBURGCM) L9 Robbery: OR (ALROBBNA) [(97) Not answered (ALROBBRY) (ALR OBBCM) L10 Assault OR (ALASL TNA) (97) Not ans we red (ALAS SLT) (xx) (ALAS LTCM) L11 Arson: OR (ALARSNNA) (97) Not answered (ALARSON) (ALARSNCM) L12 Rape: (ALRAPE) OR (ALRAPENA) (97) Not answered (ALRAPECM) L13 Homic ide/mans laughter: (ALM UR DE R) OR (ALM RD RNA) [(97) Not an swered (ALM RDRCM)

OR (ALPRSTNA) [(97) Not answered

(ALPRSTCM)

(ALPROST)

L14 Prostitution:

L15 Contempt of court:	(ALC ONTMP) (xx)	OR (ALCNTPNA) [(97) Not answered	(ALCNTPCM)	
L16 Other (specify):	(ALOTHARR) (xx)	OR (ALOARRNA) (97) Not answered		
	-		(ALOARROM)	
If "Other", specify: (ALOTHA SP)				
L17 How many of these charges resulted in convictions?				
 Do not include m is demea nor offenses from questions L18-L20 below. Convictions include fine 	es, probation, incarce rations, suspend	ded sentences, and guilty pleas.		
• If L 3-L 16 = 00, then L 17 = Not applicable				
(AL CONVCT) (xx)				
OR				
(AL CNVTNA) (96) Not applicable (97) Not answered	-			
Comments:(ALCNVTCM)				
How many times since your last ASI have you been charged with the following:				
L18 Disorderly conduct, vagrancy, public intoxication:				
(ALDISCND) (xx)				
OR (ALDCNDNA) □ (97) Not answered				
(-			
Comments:(ALDCNDCM)				
L19 Driving while intoxicated (DWI):				
(ALDWI) (xx)				
OR (ALDWINA) ☐ (97) Not answered				
(ALDITARY) — (B) (Incl. a) and (b)				
Comments:(ALDWICM)				
L20 Major driving violations:				
Moving violations: speeding, reckless driving, no license, etc.				
(ALDRVIOL) (xx)				
OR (ALDRVLNA) (97) Not answered				
(ALDA VLIM) — (31) NOLAISMENEU	-			
Comments:(ALDRVLCM)				
L21 How many months were you incarcerated since your last ASI?				
If incarcerated 2 weeks or more, round this up to 1 month. List total number of months incarc	erated (up to 99). If more than 99, cod	le 99 and enterthe number in comments.		
(AL INC RMT) (xx) months				
OR				
(ALINCRNA) ☐ (97) Not answered				
Comments:(ALINCRCM)				

L24 Are you presently awaiting charges, trial, or sentence?
0-(0) No
1-(1) Yes 97-(97) Not answered
(ALCHTRSE)
L25 What for (refers to L24)?
● Use code 03-16, 18-20. If more than one, choose most severe. Don't include civil cases, unless a criminal offense is involved.
03-03 = Shoplifting 04-04 = Probation violation
05-05 = Drug 06-06 = Forgery
07-07 = Weapons
08-08 = Burglary 09-09 = Robbery
10-10 = Assault 11-11 = Arson
12-12 = Rape 13-13 = Homicide
14-14 = Prostitution 15-15 = Contempt
99-16 = Other '
18-18 = Disorderly conduct 19-19 = DWI
20-20 = Major driving violation (ALCTSSP)
OR
(ALCTSPNA) (96) Not applicable (97) Not answered
Comments:(ALCTSPCM)
L26 How many days in the past 30 were you detained or incarcerated?
Include being arrested and released on the same day.
(ALINGOD) (xx) days
OR
(ALINSONA) (97) Not answered
Comments:(ALIN30CM)
L27 How many days in the past 30 have you engaged in illegal activities for profit? • Exclude simple drug possession. Include drug dealing, prostitution, selling stolen goods, etc. May be cross checked with question E17 under Employment/Family Support section.
(ALIP30D) (xx) days
OR
(ALIP30NA) (97) Not answered
Comments:(ALIP30CM)
For questions L28-29: Please ask participant to use the Participant Rating Scale.
L28 How's erious do you feel your present legal problems are?
Exclude civil problems
0-(0) Not at all 1-(1) Slightly
1-(1) Slightly 2-(2) Moderately 3-(3) Considerably
4-(4) Extremely (ALLP S30D)
OR

(ALLP 30 NA) (97) Not answered				
Comments:(ALL P30 CM)				
L29 How important to you now is counseling or referral f	for the se legal problems?			
	or the se legal problems? eferral to legal counsel for defense against crimina	I charges.		
O-(0) Not at all 1-(1) Slightly 2-(2) Moderately 3-(3) Considerably 4-(4) Extremely OR				
(ALLI30NA) (97) Not answered				
Comments:(ALLBOCM)				
Confidence Ratings: Is the above information significant	ly distorted by:			
L31 Participant's misre presentation? (ALMISREP) (0) No (1) Yes				
L32 Participant's inability to understand?				
(ALUNDRST) (0) No (1) Yes				
Comments:(AL COMM)				

NIDA Clinical Trials Network

CTN-ASI Lite v1.0: Medical Status (ASM)

Web Version: 1.0; 1.00; 12-17-13

Segment (PROTSEG): B Visit number (VISNO):

CTN-ASI Lite v. 1 Follow-Up: Medical Status

M1 Since your last ASI, how many times have you been hospitalized for medical problems?

- Include O.D.'s and D.T.'s. Exclude detox, alcohol/drug, psychiatric treatment and childbirth (if no complications).
- Enter the number of **overnight** hospitalizations for medical problems.

(AMHOSPTM) (xx) times

OR

(AMHOSPNA) (97) Not answered

Comments:(AMHOSPCM)

M4 Are you taking any prescribed medication on a regular basis for a physical problem?

- Medication prescribed by a M.D. for medical conditions; not psychiatric medicines.
- Include medicines prescribed, whether or not the participant is currently taking them.
- The intent is to verify chronic medical problems.



 Include Workers' Compensation, exclude psychiatric disability. (AMPENSPD) If "Yes", specify:(AMPNPDSP) Comments: (AMPNDCM) How many days have you experienced medical problems in the past 30 days? • Do not include ailments directly caused by drugs/alcohol. • Include flu, colds, etc. Include serious ailments related to drugs/ alcohol, which would continue even if the participant were abstinent (e.g., cirrhosis of liver, abscesses from needles, etc.). (AMPRB30D) (xx) days OR (AMPR30NA) (97) Not answered Comments:(AMPR30CM) For questions M7 & M8, please ask participant to use the Participant Rating Scale. How troubled or bothered have you been by these medical problems in the past 30 days? • Restrict response to problem days of question M6. (AMPBR30D) OR (AMPB30NA) (97) Not answered Comments:(AMPB30CM)

M6

М7

	(AMMTI30D)							
	OR							
	(AMMI30NA)	(97) Not answered						
	Comments:(AMM	1130CM)					4	
Confid	ence Ratings: Is	the above information	significa	ntly distorted	hv [.]			
			o igi iii io u	unity distorted				
M10	Participant's mis	srepresentation?						
	(AMMISREP)	(0) No (1) Ye	i					
M11	Participant's ina	bility to understand?						
	(AMUNDRST)	(0) No (1) Ye	S					
0	. (40.400.44)	n						
Comm	ents: <i>(ASMCOMM</i>))						

• Refers to the need for new or additional medical treatment by the participant.

CTN-ASI Lite v1.0: Psychiatric Status (ASP) Web Version: 1.0; 1.00; 12-17-13 Segment (PROTSEG): B Visit number (VIS NO): CTN-ASI Lite v. 1 Follow-Up: Psychiatric Status How many times since your last ASI have you been treated for any psychological or emotional problems? • Do not include substance abuse, employment, or family counseling. Treatment episode = a series of more or less confinuous visits or treatment days, not the number of visits or treatment days. Enter diagnosis in Comments if known. P1 In a hospital or inpatient setting? (AP PIHSPX) (APPIHPNA) [(97) Not answered Comments:(APPIHCM) P2 Outpatient/private patient? (AP POHSPX) (APPOHPNA) (97) Not answered Comments:(APPOHPCM) P3 Do you receive a pension for a psychiatric disability? 0-(0) No 1-(1) Yes 97-(97) Not answered Comments:(APPENPCM) Have you had a significant period of time (that was not a direct result of drug/alcohol use) in which you have: A Past 30 Days Comments P4 Experienced serious depression-sadness, hopelessness, loss of interest, difficulty with daily function? 0-(0) No 1-(1) Yes 97-(97) Not answere (APDEPCM) (AP DEP 30D) P5 Experienced serious anxiety/tension-uptight, unreasonably worried, inability to feel relaxed? 0-(0) No 1-(1) Yes 97-(97) Not answered (APA NXCM) (AP ANX 30D) P6 Experienced hallucinations-saw things or heard voices that other people did not see or hear? 0-(0) No 1-(1) Yes (APHLC CM) 97-(97) Not answered (APHLC30D)

P7 Experienced trouble understanding, concentrating, or remembering?	0-(0) No			
	1-(1) Yes	(APCNCCM)		
	97-(97) Not answered			
For questions P8-P10, participant could have been under the influence of alcohol/drugs				
	A Past 30 Days		Comments	
P8 Experience of trouble controlling violent behavior including episodes of rage, or violence?	0-(0) No			
 Participant can be under the influence of a lcohol/drugs. 	1-(1) Yes 97-(97) Not answered (APV	/LTCM)		
	(AP VLT30D)			
P9 Experience d serious thoughts of suicide?	0-(0) No			
 Participant's eriously considered a plan for taking his/her life. 	1-(1) Yes	OSCM)		
	97-(97) Not answered (APT	00000/1		
P10 Attempted suicide?				
Include actual suicidal gestures or attempts.	0-(0) No 1-(1) Yes			
morado dotado o de order godelado de detemplo.	97-(97) Not answered	ISUCM)		
	(AP ASU30D)			
P11 Been prescribed medications for any psychological/emotional problem?	0-(0) No			
 Prescribed for the participant by MD. Record "Yes" if a medication was prescribed even if the participant is not taking it. 	1-(1) Yes 97-(97) Not answered (APM	л EDCM)		
	(AP MED 30 D)			
P12 How many days in the past 30 have you experienced these psychological or emotional prof	blems?			
 This refers to problems noted in questions P4-P10. 				
(APPRB30D) (xx) days				
OR				
(APPR 30NA) (97) Not answere d				
				
Comments:(APPR30CM)				
Continents.(ALT NOO CW)				
For questions P13-P14, please ask participant to use the Participant Rating Scale.				
•				
P13 How much have you been troubled or bothered by these psychological or emotional proble	ms in the past 30 days?			
Participant's hould be rating the problem days from question P12.				
0-(0) Not at all 1-(1) Slightly				
2-(2) Moderately				
3-(3) Considerably 4-(4) Extremely				
(APPBR 30 D)				
OR				
(APPB30NA) (97) Not answered				
Comments:(APPB30CM)				
P14 How important to you now is treatment for these psychological or emotional problems?				
0-(0) Not at all				
1-(1) Slightly 2-(2) Moderately				
3-(3) Considerably				
(APPTI30D) 4-(4) Extremely				
OR				
(APPI30NA) (97) Not answered				
Comments:(APPI30CM)				

Confidence Ratings: Is the above information significantly distorted by:	 	
P22 Participant's misrepresentation? (APMISREP) □ (0) No □ (1) Yes		
P23 Participant's inability to understand? (APUNDRST) □ (0) No □ (1) Yes		
Comments: (APCOMM)		

IDA Clinical Trials Notwork	

Concise Health Risk Tracking (CHRT) - Participant Rated Module (CHP)

1.02;04-09-14

							, ,		
gment (PROTSEG): B sit number (VISNO):									
Date of assessment (CHPA SMDT)					(mm.kld/yyy	y)			
Please rate the extent to which each of the following statemer Forexample, if you feel the statement very accurate				a rating of "Strongly A	Agree." If you feel the statement	tisnotatall how you have bee	en feeling in the pastweek, yo	ou would give a rating of "Strong	gly Disagree."
	S trongly Disagree	Disagree	Neither A gree nor Disa gree	Agree	Strongly Agree				
1. I feel as if things are never going to get better.	(CHNVRBTR)								
2. I have no future.	(CHNOFUTR)								
3. It seems as if I can do nothing right	(CHNORGHT)								
. Everything I do turns out wrong.	(CHWRONG)								
There is no one I can depend on.	(CHDEPEND)								
The people I care the most for are gone.	(CHPPLGNE)								
I wish my suffering could just all be over.	(CHSUFFER)								
I feel that there is no reason to live.	(CHRSLIVE)								
I wish I could just go to sleep and not wake up.	(CHSLEEP)								
). I find myself saying or doing things without thinking.	(CHNOTHNK)								
I often make decisions quickly or "on impulse."	(CHIMPULS)								
I often feel irritable or easily angered.	(CHIRRITE)								
Toften overreact with anger or rage over minor things.	(CHOVRRCT)								
14. I have been having thoughts of killing myself.	(CHKILLMS)								

Comments: (CHPC OM M)

16. I have a plan to kill myself.

© 2008 UT Southwestern Medical Center at Dalla's

15. I have thoughts about how I might kill my self.

(CHHOWKIL)

(CHPLNKIL)

	NIDA Clinical Trials Network	
	BUP-NX Dose Log (D51)	
	BUF-NA Dose Log (D31)	Web Version: 1.0; 3.00; 06-11-14
Segment (PROTSEG): B Visit number (VIS NO):		
Date of visit: (D51 DSEDT)	(mm.ldd/yyyy)	
1. Wsit type {D51VSTYP}	1-Induction 2-Dispensing 3-Non-dispensing 4-Participant not yet inducted	
2. Prescrib ed daily dose: (D51 DOSE)	(xx)	
3. Number of days with a missed dose since the last visit:(D51MSDSE)	(xx)	
4. Were films returned?(D51 RTRNY) a. Number of 4mg films returned: (D51N4FRT)	No Yes (xxx)	
b. Number of 8mg films returned: (D51N8FRT)	(xxx)	
5. Was medication dispensed?(D51BUPDD)	□ No □ Yes	
a. Number of 4 mg films dispensed: (D5 1NM4FD) b. Number of 8 mg films dispensed: (D5 1NM8FD)	(xxx)	
	(xxx)	
Comments: (D6 1C OMM)		
	·	

NIDA Clinical Trials Network

Demographics (DEM)

Web Version: 1.0; 2.02; 07-11-14

Date of birth:(DEBRTHDT)		(mm/dd/yyyy)
2. Age:(DEAGE)		(xx)
3. Gender:(DEGENDER)		☐ Male ☐ Female ☐ Don't know ☐ Refused
	or herself to be Hispanic/Latino?(<i>DEHISPNC</i>) epresents his or her Hispanic origin or	1-Puerto Rican 2-Dominican (Republic) 3-Mexican/Mexicano 4-Mexican American 5-Chicano *Additional Options Listed Below
5. What race does the participant cons (Check all that apply)	sider him or herself to represent:	
White:	(DEWHITE)	
Black/ African American:	(DEBLACK)	
Indian (American):	(DEAMEIND)	
Alaska native:	(DEALASKA)	
Native Hawaiian:	(DEHAWAII)	
Guamanian:	(DEGUAM)	
Samoan:	(DESAMOAN)	
Other Pacific Islander:	(DEPACISL) Specify: (DEPACIS	(08
Asian Indian:	(DEASAIND)	
Chinese:	(DECHINA)	
Filipino:	(DEFILIPN)	
Japanese:	(DEJAPAN)	
Korean:	(DEKOREA)	
Vietname se:	(DEVIETNM)	
Other Asian:	(DEASIAN) Specify: (DEASIAC	οη
Some other race:	(DERACEOT) Specify: (DERACE	ESP)
-OR-		
Don't know:(DERACEDK)		
Refused: (DERACERF)		

6. What is the highest grade or level of school the participant has completed or the highest degree they have received? (DEEDUCTN)	00-Never attended / kindergarten only 01-1st grade 02-2nd grade 03-3rd grade 04-4th grade *Additional Options Listed Below
7. We would like to know about what the participant does is he/she working now, looking for work, retired, keeping house, a student, or what? (DEJOB)	01-Working now 02-Only temporarily laid off, sick leave, or maternity leave 03-Looking for work, unemployed 04-Retired 05-Disabled, permanently or temporarily *Additional Options Listed Below
If "Other", specify:(DEJOBSP)	
8. Is the participant married, widowed, divorced, separated, never married, or living with a partner? (DEMARTL)	01-Married 02-Widowed 03-Divorced 04-Separated 05-Never married *Additional Options Listed Below
Comments:(DEMCOMM)	

Additional Selection Options for DEM If "Yes", indicate the group that represents his or her Hispanic origin or ancestry: 6-Cuban 7-Cuban American 8-Central or South American 9-Other Latin American 99-Other Hispanic 98-Refused 97-Don't know 05-5th grade

What is the highest grade or level of school the participant has completed or the highest degree they have received?

06-6th grade

07-7th grade

08-8th grade

09-9th grade

10-10th grade

11-11th grade

12-12th grade, no diploma

13-High school graduate 14-GED or equivalent

15-Some college, no degree

16-Associate's degree: occupational, technical, or vocational program 17-Associate's degree: academic program

18-Bachelor's degree (e.g., BA, AB, BS, BBA)

19-Master's degree (e.g., MA, MS, MEng, MEd, MBA)

20-Professional school degree (e.g., MD, DDS, DVM, JD)

21-Doctoral degree (e.g., PhD, EdD)

98-Refused

97-Don't know

We would like to know about what the participant does -- is he/she working now, looking for work, retired, keeping house, a student, or what?

06-Keeping house

07-Student

99-Other

Is the participant married, widowed, divorced, separated, never married, or living with a partner?

06-Living with partner

98-Refused

99-Don't know

IDA .	Clinic	al Ti	ria le	Moty	work

Segment (PROTSEG): B

1. Did the participant discontinue study medication early?(E OE ARLY)

Primary reason for not completing study medication: (EOSTOP 51)

If "Other", specify: (EOSTOPSP)

2. Date of last taken buprenorphine dose: (EODRUGDT)

Comments:(EOMCOMM)

End of Medication (EOM)

Web Version: 1.0; 4.00; 08-05-15

□ No □ Yes	
1-Participant became pregnant 2-Participant unable to tolerate side effects 3-Participant continued to experience intolerable side effects after a dose reducti 4-Contraindicated concomitant medication 5-Participant refused, non-specific	on
*Additional Options Listed Below	
(mm/dd:ly yyy)	

Additional Selection Options for EOM

Primary reason for not completing study medication:
6-Participant left study and never returned
7-Clinical deterioration: new onset of psychiatric or medical condition
8-Physical liness or condition that precludes taking study medication
9-Participant feels study treatment no longer necessary, cured
10-Participant feels study treatment no longer necessary, not working
11-Participant became in carcerated
12-Participant with drew consent
13-Participant moved from area
14-Participant decessed
15-Participant moved from area

D^A	CILL	~ ~ l .	T-i-	lo Nie	Aur orle

	0051B (ENR)	Version: 1.0: 2.00: 09-10-15
	Web	version: 1.0; 2.00; 09-10-15
Date of assessment (R1ASMDT)	(mm.kid'yyyy)	
Inclusion Criteria In order to meet eligibility ALL Inclusion answers must be "Yes".		
1. Participant is 18 years of age or older? (R1PTAGE)	□ No □ Yes □ Unknown	
2. Participant meets DSM-5 criteria for opioid-use disorder (heroin and/or prescription opioids)? (R1 OPIDEP)	□ No □ Yes □ Unknown	
3. Partic ipant has used opioids other than as specifically prescribed within thirty days prior to consent? (R10PIUSE)	No	
4. Participant is seeking treatment for opioid dependence and willing to accept "agonist-based" or "antagonist-based" therapy?(R1SEEKTX)	No Yes Unknown	
If "No", specify:(R1THRPSP)	O-Participant did not want medication 1-Participant did not want buprenorphine 2-Participant did not want naltrexone 3-Participant preferred another treatment	
5. Participant is female of childbearing potential, and agrees to use acceptable birth control methods during participation in the study?(R1BCUSE)	No Yes Not assess ed Not applicable	
6. Participant is in good-enough health, as determined by the study physician on the basis of medical history, review of systems, physical examand laboratory assessments, to permit treatment with XR-NT X or B UP-N X?(R IHEAL TH) 7. Participant is able to provide written informed consent? (R ININFORM)	No Yes Unknown	
8. Participant is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study? (R1ENGLSH)	□ No □ Yes □ Unknown	
Exclusion Criteria In order to meet eligibility ALL Exclusion answers must be "No".		
1. Participant has a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, or compromise study findings or would prevent the participant from completing the study? Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments (b) Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as as sessed by history and/or clinical interview (c) Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative deb oxifications may be included)(R*IPSYCH)		
2. Participant has LFTs greater than 5 times upper limit of normal?(R1LFTS)	No	
3. Participant has suicidal or homicidal ideation that requires immediate attention? (R1 SUIC DE)	No Yes Unknown	
of the Vivitro® diluent?(R1ALERGY)	□ No □ Yes □ Unknown	
 Participant is on maintenance of methadone at doses of 30 mg or greater at the time of signing consent? (R 1M TDMNT) Participant has presence of pain of sufficient severity as to require ongoing pain management with oploids? (R1 PAIN) 	No Tyes Unknown	
 Participant has presence or pain or surricent seventy as to require on going pain management with opcodes (κτ ΡΑΙΙΝ) Participant has pending legal action or other reasons that might prevent an individual from completing the study?(R1LEGAL) 	No Yes Unknown	
8. Participant has penalty legal action of other reasons that might prevent an involudation completing the study (R IZESAE) 8. Participant is female of child bearing potential and currently pregnant, breastfeeding, or planning on conception? (R1PREGNT)	No Yes Unknown No Yes Notassessed Notapplicable	
9. Participant has a body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat fissue over the butbocks, emaciation)?(R1HABTUS)		
Eligibility for Randomization		
Did the participant complete the screening visit? (R1 CM PSC R)	□ No □ Yes	
If *No*, specify:(R*INCMPSP)	0-Participant dropped out of CTP 1-Participant did not meet eligibility criteria 2-Participant did not want research 99-Other	
If "Other", specify:(R1NCMOTH)		
2. Is the participant eligible for the study? (R1ELGSTY)	□ No □ Yes	
a. In the 7 day period prior to detox admission, on a verage how many bags (or equivalent) of IV heroin per day did the participant report using?(R1HERBAG)	G)	
b. Last (licit or illicit) opioid use prior to randomization entered on the Detoxification Utilization Summary form?(R1LSTOPI)	□ No □ Yes	
3. Will the participant be randomized?(Rf ELGRDM)	□ No □ Yes	

If "No", specify: (R1NORSP)	O-Participant dropped out of CTP 1-Participant did not meet eligibility criteria 2-Participant did not want research 99-Other
If "Other", specify:(R1 OTHRSP)	
4. Have all eligibility criteria been reviewed by the study physician?(R1PHYREV) If "Yes", review date:(R1PHRVDT)	□ No □ Yes (mm.kld/yyyy)
Commerts: (R1 COMM)	

MID A	Clini	riale	NIO	work

The Hamilton Rating Scale for Depression (HAM)

(mm/dd/yyyy)

	The Hamilton
-	nt (PROTSEG): B mber (V.S.NO):
Date	of assessment (HAMASMDT)
To r	ate the severity of depression, administer this questionnaire. The higher the score, the more severe the depression.
1.	DEP RESS ED MOOD (Sadness, hopeless, helpless, worthless)
	0-(0) Absent 1-(1) These feeling states indicated only on questioning 2-(2) These feeling states spontaneously reported verbally 3-(3) Communicates feeling states non-verbally- i.e., through facial expression, posture, voice, and t 4-(4) Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal com
2.	FEELINGS OF GUILT
	0-(0) Absent 1-(1) Self reproach, feels he has let people down 2-(2) Ideas of guilt or rumination over past errors or sinful deeds 3-(3) Present illness is a punishment. Delusions of guilt 4-(4) Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations
3.	SUICIDE
	0-(0) Absent 1-(1) Feels life is not worth living 2-(2) Wishes he were dead or any thoughts of possible death to self 3-(3) Suicide ideas or gesture 4-(4) Attempts at suicide (any serious attempt rates 4)
4.	NSOMNIA EARLY
	0-(0) No difficulty falling asleep 1-(1) Complains of occasional difficulty falling asleep - i.e., more than 1/2 hour 2-(2) Complains of nightly difficulty falling asleep (HAINSMER)
5.	NSOMNIA MIDDLE
	0-(0) No difficulty 1-(1) Participant complains of being restless and disturbed during the night 2-(2) Waking during the night - any getting out of bed rates 2 (except for purposes of voiding)
6.	NSOMNIA LATE
	0-(0) No difficulty 1-(1) Waking in early hours of the morning but goes back to sleep 2-(2) Unable to fall asleep again if he gets out of bed
7.	WORK AND ACTIVITIES
	0-(0) No difficulty 1-(1) Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies 2-(2) Loss of interest in activity, hobbies or work-either directly reported by patient, or indirect i 3-(3) Decrease in actual time spent in activities or decrease in productivity 4-(4) Stopped working because of present illness
	(HAWRKACT)

8. RETARDATION: PSYCHOMOTOR

(Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)

Web Version: 1.0; 1.00; 10-03-13

	0-(0) Normal speech and thought 1-(1) Slight retardation at interview 2-(2) Obvious retardation at interview 3-(3) Interview difficult 4-(4) Complete stupor
9.	AGITATION
	0-(0) None 1-(1) Fidgetiness 2-(2) Playing with hands, hair, etc. 3-(3) Moving about, can't sit still 4-(4) Hand wringing, nail biting, hair-pulling, biting of lips
10.	ANXIETY (PSYCHOLOGICAL)
	0-(0) No difficulty 1-(1) Subjective tension and irrability 2-(2) Wornying about minor matters 3-(3) Apprehensive attitude apparent in face or speech 4-(4) Fears expressed without questioning
11.	ANXIETY SOMATIC: Psychological concomitants of anxiety, (i.e., effects of autonomic overactivity, "butterflies," indiges fon, stormach crar belching, diarrhea, palpitations, hyperventilation, parathesia, sweating, flushing, tremor, headache, urinary frequency). Avoid asking about possible medication side effects (i.e., dry mouth, constpation)
	O-(0) Absent 1-(1) Mild 2-(2) Moderate 3-(3) Severe 4-(4) Incapacitating
12	SOMATIC SYMPTOMS (GASTROINTESTINAL)
	0-(0) None 1-(1) Loss of appetite but eating without encouragement from others. Food intake about normal 2-(2) Difficulty eating without urging from others. Marked reduction of appetite and food intake (HASOMGAS)
13.	O-(0) None 1-(1) Heaviness in limbs, back and head. Backaches, headache, muscle aches. Loss of energy and fatigab 2-(2) Any clear-cut symptom rates 2
	(HASOMGEN)
14.	GENITAL SYMPTOMS (Symptoms such as: loss of libido; impaired sexual performance; menstrual disturbances) 0-(0) Absent 1-(1) Mild 2-(2) Severe
	(HAGENSYM)
15.	O-(0) Not present 1-(1) Self-absorption (bodily) 2-(2) Preoccupation with health 3-(3) Frequent complaints, requests for help, etc. 4-(4) Hypochondriacal delusions
16.	LOSS OF WEIGHT A. When rating by history:
	0-(0) No weight loss 1-(1) Probably weight loss associated with present illness 2-(2) Definite (according to participant) weight loss (HAWEIGHT)
17.	INSIGHT
	0-(0) Acknowledges being depressed and ill 1-(1) Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest 2-(2) Denies being ill at all

Commerts:(HA MCOMM)	
Copyrigh P 1997 Glaxo Wellcome Inc. All rights reserved. Adapted from Hedlung and Vieweg. The Hamilton rating scale for depression, Journal of Operations	al Psychiatry, 1979;10(2):149-165.

Injection Site Abnormality (INA)

Segment (PROTSEG): B

Note: If abnormality results in a SAE, complete SAE CRFs.

Abnormal Event If "Other", specify in comments	Event Start Date (mm/dd/yyyy)	Severity	Treatment	Event Resolution Date (mm/dd/yyyy)	Comments
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below	(NESDT1)	(INESVR1) Mild Moderate Severe	(NETRT1)	(INERDT1)	(INE COM1)
1-Pain 2-Tendermess 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below	(NESDT2)	(INESVR2) Mild Moderate Severe	(NETRT2)	(INE RD T2)	(INE COM2)
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Belov	(NESDT3)	(INE SVR3) Mild Mode rate Sever e	(NETRT3)	(INE RD T3)	(INE COM3)
1-Pain 2-Tendermess 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Belov	(NESDT4)	(INE SVR4) Mild Moderate Severe	(NETRT4)	(INE RD T4)	(INE COM4)
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Belov	(NESDT5)	(INE SVR 5) Mild Mode rate Sever e	(NETRT5)	(INE RD T5)	(INE COM5)
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Belov	(INESDT6)	(INESVR6) Mild Moderate Severe	(NETRT6)	(INE RD T6)	(INE COM6)
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Belov	(NESDT7)	(INESVR7) Mild Moderate Severe	(NETRT7)	(INERD T7)	(INE COM7)
1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) 8. (NFTYP8)	(NESDT8)	(INE SVR8) Mild Moderate Severe	(NETRT8)	(INE RD T8)	(INE COM8)

Web Version: 1.0; 1.00; 10-04-13

9. (INETYP9	1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below	(NESDT9)	(INE SVR9) Mild Moderate Severe	(NETRT9)	(INE RDT9)	(INE COM9)
10. (INETY P	1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below	(NESDT10)	(INESVR10) Mild Moderate Severe	(NETRT10)	(INERDT10)	(INECOM10)
11 . (INE TY P	1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below	(NESDT11)	(INESV11) Mild Moderate Severe	(NETRT11)	(INE RDT1 1)	(INE COM1 1)
12. (INETY P	1-Pain 2-Tenderness 3-Induration 4-Swelling 5-Erythema (redness) *Additional Options Listed Below 12)	(NESDT12)	(INESV12) Mild Moderate Severe	(INETRT12)	(INE RDT12)	(INECOM12)
Comments: (IN	ACOMM)					_

Additional Selection Options for INA Event 1 type 6-Bruising 7-Pruritus 8-Nodule 9-He matoma 10-Abs cess 11-Sterile ab scess 12-Necro sis 13-C ellulitis 99-Other

	NIDA Clinical Trials Network	
	Induction Failure (INF)	
		Web Version: 1.0; 1.01; 05-12-14
Date induction failed: (INFAILDT)	(mm Æd/yyyy)	
1. Why was the participant not induced into a treatment?(INREAS ON)	O-Participant could not tolerate detoxification 1-Participant failed naloxone challenge 2-Paricipant failed to provide a negative urine sample 3-Participant left prior to induction 4-Participant rejected treatment assignment *Additional Options Listed Below	
Comments: (INFC OM M)		

Additional Selection Options for INF Why was the participant not induced into a treatment? 5-Participant met criteria for relapse 6-Participant reached end of induction window

	In Note	
Clinic	is Net	work

XR-NTX Administration (INJ) Web Version: 1.0; 2.00; 12-30-13 Segment (PROTSEG): B Injection number (INJNUM): Date of injection: (INJ INJDT) (mm/dd/yyyy) 1. Location of previous injection: (INPREV) Right buttock Left buttock 2. Injection location: (ININULOC) Right buttock Left buttock 3. Time injection given (24 - hourformat): (ININUTM) (hh:mm) 4. Did you experience difficulty with XR-NTX administration?(INDIFFCT) □ No □ Yes If "Yes", describe: (INDIFRES) Comments: (INJC OMM)

Additional Selection Options for INJ Injection number (INJNUM) (key field): 1-1 2-2 3-3 4-4 5-5 6-6 7-7

	NIDA Clinical Trials Network	
	Injection Site Examination (INX)	Web Version: 1.0; 1.01; 10-30-13
Segment (PROTSEG): B Injection number (INJNUM):		web version. I.u. I.u., 1050013
Date of examination:(INXASMDT)	(mm /t d/yyyy)	
Location of previous injection: (INJP REV) 1. Location of injection: (INJLOC) 2. Is this injection site normal? (INJOK)	Right buttock Right buttock Left buttock No Yes	
If the injection site is "abnormal", complete the Injection Site Abnormality Log. Note: If this event is an SAE, you must complete the AE forms.	NO 1 Yes	
Comments:(INXCOMM)		
	'	

Additional Selection Options for INX	
Injection number (INJNUM) (key field):	
1-1 2-2 3-3 4-4 5-5 6-6 7-7	
2·2 3-3	
4-4 5-5	
6-6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
**	

א חו	Clini	riale	Motu	ork.

Clinical Laboratory Tests (LAB)

Segment (PROTSEG): B Visit number (VIS NO):

ab collection	date:(LABDATE)			
	Test	Result	Date of Collection (mm/dd/yyyy)	Abstracted from Medical Record
	Test	Result		
	Aspartate Amin otransfer ase (AST/SGOT)	(LAAST) (xx xx.x) IU/L	(LAAS TDT)	(LA ASTMR) Yes
LFTs	Alanine Aminotransferase (ALT/SGPT)	(LAALT) (XXXX.X) U/L	(LAAL TDT)	(LA ALTMR) Yes
LFIS	3. Albumin	(LAALBUMN) (x.x) g/dL	(LAALBDT)	(LA ALBM R) Yes
	4. Total Bilirubin	(LABILRBT) (xx.x) mg/dL	(LABIL DT)	(LA BILMR) Yes
	5. Hep B surface antigen (HB sAG)	(LAHBSAG) Negative Positive	(LAHBAGDT)	(LA HBAGMR) Yes
Hepatitis	6. Hep B surface antibody (HB sAB)	(LAHBSAB) Negative Positive	(LAHBABDT)	(LA HBAB MR) ☐ Yes
	7. Hep C antibody	(LAHEPC) Negative Positive	(LAHEPCDT)	(LA HEPCMR) Yes
	•			
HIV	8. HIV antibody	(LAHIVAB) Negative Positive	(LAHNDT)	(LA HIVM R) Yes

Comments: (LA BCOM M)

Web Version: 1.0; 6.03; 09-07-16

D A	Climia	of Table	ale Na	twork.
	Clinic		ais Ne	etwork.

MM Community Treatment (MMC)

Web Version: 1.0; 2.01; 06-02-16

Segment (PROTSEG):	В
Visit number (VIS NO):	

Date of assessment (MMCASMDT)

- 1. Is the participant continuing to receive treatment in the community as planned? (MMTXPLAN)
- 2. What treatment(s) is the participant engaging in:
- a. Medication assisted treatment (MAT) with buprenorphine maintenance: (MMBUP)
- b. Medication assisted treatment (MAT) with injectable naltrexone:(MM VIVTRL)
- c. Medication assisted treatment (MAT) with oral nattrexone:(MMVIVORL)
- d. Medication assisted treatment (MAT) with methadone maintenance: (MMMTDMNT)
- e. Medication assisted treatment (MAT) with in patient detox: (MM INPDTX)
- f. P sychosocial: (MM PSYCH)
- g. Referral to other community-based treatment:(MM COMTRT)

- OP

Declined further treatment (MMDCLNTR)

Comments: (MM C COMM)

(mm,bl d/yyyy)	
□ No □ Yes □ Not applicable	
□ No □ Yes □ No □ Yes	
□ No □ Yes	
□ No □ Yes □ No □ Yes	
No Yes f "Yes", specify: (MMPSYCSP)	_
No Yes	

Medical Management Log (MML)

Segment (PROTSEG): B

Scheduled Medical Management Visit(s)

Week	Medical Management	Date of Visit (mm/dd/yyyy)	Comments
0	(MMYNWK00) No Yes	(MMDT00)	(MM COM MOO)
1	(MMYNWK01) No Yes	(MMDT01)	(MM COMMO1)
2	(MMYNWK02) □ No □ Yes	(MMDT02)	(MM COM MO2)
3	(MMYNWK03) No Yes	(MMDT03)	(MM COM MO3)
4	(MMYNWK04) No Yes	(MMDT04)	(MM COM M04)
6	(MMYNWK06) No Yes	(MMDT06)	(MM COM M06)
8	(MMYNWK08) No Yes	(MMDT08)	(MM COM MO8)
10	(MMYNWK10) No Yes	(MMDT10)	(MMCOMM10)
12	(MMYNWK12) No Yes	(MM DT 12)	(MMCOMM12)
14	(MMYNWK14) No Yes	(MM DT 14)	(MMCOMM14)
16	(MMYNWK16) No Yes	(MM DT 16)	(MMCOMM16)
20	(MMYNWK20) No Yes	(MM DT20)	(MM COM M2 0)
24	(MMYNWK24) No Yes	(MM DT24)	(MM COM N/2 4)
ЕОТ	(MMYNEOT) No Yes	(MM DTEOT)	(MMCOMEOT)

Un-scheduled Medical Management Visit(s)

Date of Visit (mm/dd/yyyy)	Reason If 'Other', specify in Comments section	Comments
(MMUSDT01)	0-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM01)
(MMUSDT02)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE:SAE *Additional Options Listed Below	(MMUSCM02)
(MMUSDT03)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCMO3)

Web Version: 1.0; 3.00; 12-19-14

(MMUSDT04)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCMO-4)
(MMUSDTO5)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM05)
(MMUSDTO6)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM06)
(MMUSDT07)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM07)
(MMUSDTOB)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCMOB)
(MMUSDTO9)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM09)
(MMUSDT10)	O-BUP dose adjustment 1-BUP medication replacement 2-XR-NTX off cycle injection 3-XR-NTX injection site reaction 5-AE/SAE *Additional Options Listed Below	(MMUSCM10)

Comments:(MMLCOMM)

Additional Selection Options for MML	
Ursch 1 med mgmt reason	
99-Other	

IDA Clinical Trials Notwork	

Management Termination (MMT)	
	Web Version: 1.0; 1.01; 06-02-16
meets the primary outcome of an opicid relapse event and is referred to community treatr	nent, or MM treatment ends for other reasons. Note: participants may discontinue study medications for
(mm/dd/yyyy)	
1-End of study treatment period 2-Relapse (positive urines or self-report) 3-Relapse (missing urines) 4-Adverse event 5-Participant declined further MM study treatment visits *Additional Options Listed Below	
No	
	I-End of study treatment period -End of study treatment -End of study tre

Additional Selection Options for MMT Whydid Medical Management (MM) treatment end? 99-Other (e.g., othersafety concerns, Pidscreton)		

	NIDA Clinical Trials Network	
	Missed Visit Form (MVF)	
Segment (PROTSEG): B Visit number (VSNO):		Web Version: 1.0; 1.00; 12-06-13
Reason for missed visit: (MVREASON)	1-Participant failed to return to clinic and unable to contact 2-Participant unable to attend visit (e.g., no childcare, transportation, schedule conflict) 3-Participant on vacation 4-Participant illness 5-Participant in hospital, in-patient, or residential treatment "Additional Options Listed Below	
If "Other", specify:(MV OTHRSP)		

Comments: (MV FC OMM)

Additional Selection Options for MVF Reason for missed visit: 6-Participant moved from area 7-Participant incar cera ted 8-CTP/Site doised 9-Participant withdrew consent 10-Participant deceased 99-Other

Non-CTP / Study Medical and Other Services (NMS)

Web Version: 1.0; 1.00; 10-14-13

Segment (PROTSEG): B Visit number (V.S.NO):		
Date of assessment (NMS ASMDT)	(mm/dd.ly.yyy)	
When did the participant last complete this form (NMLSTFDT)	(mm/dd/yyyy)	
The following questors are about the services you've received in the past 30 days, besides what you've received in this research study.		
1. Are you currently receiving substance abuse treatment services from this substance abuse treatment program (CTP)? (NM CTPSER)	□ No □ Yes	
Have you participated in an (other) outpatient treatment program for drug or alcohol problems? (Do not include your participation in this study or the services directly related to this study or services received from this substance abuse treatment program.) (NM OUTSER)	□ No □ Yes	
a. How many days have you participated?(NMOUTDAY)	(xx) days	
b. How many hours do you attend the program in a typical week? (NM OUTHR)	(xx) hours	
c. Are you, or have you been, required by the criminal justice system to attend treatment?(NMOUTCJ)	No Yes	
3. Have you been admitted into a residential program for detoxor for other services? (NMRDTX)	□ No □ Yes	
a. How many admissions? (NM RD TXNO)	(xx) admissions	
b. How many nights altogether for all stays?(NMRDTXNG)	(xxx) nights	
Have you been admitted into a hospital for detox?(NMHDTX) a. How many admissions? (NMHDTXNO)	No Yes	
	(xx) admissions	
b. How many nights allogether for all stays?(NMHDTXNG)	(xx) nights	
5. Have you been admitted to the hospital for any other reason? (NMHS PTL)	□ No □ Yes	
a. How many times were you admitted? (NMHSPNO)	(xx) admissions	
b. Were any admissions for psychiatric or emotional reasons?(NMHSPPS Y)	□ No □ Yes	
c. How many nights altogether for all stays?(NMHSPNG)	(xx) nights	
Have you visited an emergency room and not been admitted to the hospital? (NM ER)	E	
How many times did you visit the emergency room?(NMERNO)	No Yes	
now many times and you visit the emergency room: (NIMECNIO)	(xx) visits	
 Outside of the services or programs mentioned above, have you seen a flerapist, that is a psychiatrist, psychologist, counselor, or social worker for psychological or emotional problems?(NMMTHLTH) 	□ No □ Yes	
How many times did you see a psychiatrist, psychologist, counselor or social worker?(NMMTHLNO)	(xx) times	
8. Outside of the services or programs mentioned above, have you seen a therapist, that is a psychiatrist, psychologist, counselor, or social worker for alcohologue groblems? (NMMDDRG)	□ No □ Yes	
How many times did you see a psychiat ist, psychologist, counselor or social worker?(NMMDGNO)	(xx) times	
9. Have you visited a medical office, not including your therapis (? (Include all visits to a physician, nurse, nurse practitioner, or physician's assistant.) (IMM/MED OFF)	□ No □ Yes	
a. How many visits to a medical office have you had? (NIM MEDNO)	(xx) visits	
b. How many of these visits did you see a doctor? (NMMEDSEE)	(xx) visits	
10. Have you attended AA, NA, or CA meetings? (NMAA)	□ No □ Yes	
For how many days ?(NMAA DAY)	(xx) days	
TO THE MAIN GOVERNMENT OF THE STATE OF THE S	(xx) days	
11. Are you currently prescribed any medication for the treatment of substance abuse?(NMRXMED)	□ No □ Yes	
a. If "Yes", which of the following medications have you been prescribed?		
Depot Natrexone (NMRXVVTD)	No Yes	
Nalt exone (MMR XVVTL)	No Yes	
Suboxone(NMRXSBX) Subutex(NMRXSBTX)	No Yes	
Subutex(NW RXSB1X) Methadone (NM RXMETH)	No Yes	
Buprenorphine(NMRXBUP)	□ No □ Yes □ ···	
Acamprosate(NMRXACS)	□ No □ Yes	
non-product (minor to o)	□ No □ Yes	

	Antabuse/Disulfiram(NM RXDSM)		□ No □	Yes	
	Other(NMRXOTR)		□No	Yes Specify: (NMRXOTSP)	
	b. How many total days did you take this/these medications?(NMMEDDAY)			(xx)	
12. F	Have you had health insurance?(NMINSURE)		□ No □	Yes	
	a. Did you have Medicaid?(NMINSMED)		□No□	Yes	
	b. Did you have other public insurance?(NMINSPUB)		□ No □	Yes	
	c. Do you have private health insurance?(NMINS PRV)		□ No □	Yes	
	d. Have you spent time uninsured? (NMINSNO)		□ No □	Yes	
13. F	Have you had a job? This includes <u>any job for which you have been paid (</u> including under-the-table wo	rk.)(NM WORKIN)	□ No □	Yes	
	a. How many days have you been paid for working? (NM WRKDAY)			(xx) days	
	b. Including overtime, how many hours per week do you work on this job? (NM WRKHRS)			(xxx) hours	
	c. Including tips and bonuses, what is your hourly rate on this job, before taxes?(NMWRKRTE)			(\$\$\$.\$\$) per hour	
1	Now Iwould like to ask you some questions about your legals tatus. Iwant to remind you all informatio	on is kept strictly confidential. Legal in	formation will not be availab	ole to anyone outside this research stud	dy.
14. F	How many days have you participated in criminal activities (excluding drug use)?(NMCRMACT)			(xx) days	
15. H	How many days were you detained or incarce rated (spent overnight in jail)? (NMCRMINC)			(xx) days	
F	Have you committed, been charged with, or been convicted of (answer all questions below):				
		Committed	If "Yes",	Charged	Convicted
			Number of Days: (xx)		
	16. Drug charges (not drug dealing)	N/A	N/A	(NMDCCHAR) No Yes	(NMDCCONV) No Yes
	17. Drug dealing	(NMDDCOMT) No Yes	(NMDDDAYS)	(NMDDCHAR) No Yes	(NM DD CONV) No Yes
	18. Sho plifting/retail the ft	(NMSLCOMT) No Yes	(NM SL DAYS)	(NMSLCHAR) No Yes	(NMSLCONV) No Yes
	19. Theff/non-retail	(NMTFCOMT) No Yes	(NMTFDAYS)	(NMTFCHAR) No Yes	(NMTFCONV) No Yes
	20. Robbery	(NMRBCOMT) No Yes	(NMRBDAYS)	(NMRBCHAR) No Yes	(NMRBCONV) No Yes
	21. Household burglary	(NMHHCOMT) ☐ No ☐ Yes	(NMHHDAYS)	(NMHHCHAR) No Yes	(NMHHCONV) No Yes
	22. Auto thett	(NMATCOMT) No Yes	(NMATDAYS)	(NMATCHAR) No Yes	(NMATCONV) No Yes
	23. Aggravated assault	(NMAACOM T) No Yes	(NMAADAYS)	(NMAA CHAR) No Yes	(NMAACONV) No Yes
	24. Sexual assault	(NMSACOM T) No Yes	(NM SADAYS)	(NMSA CHAR) No Yes	(NMSACONV) No Yes
	25. Driving while intoxicated	(NMDICOMT) No Yes	(NMDIDAYS)	(NMDICHAR) No Yes	(NM DIC ON V) No Yes
	26. Other, specify: (NMOTCRSP)	(NMOTCOMT) No Yes	(NM OTDAYS)	(NMOTCHAR) No Yes	(NMOTCONV) No Yes
_					
	Comments: (NM SC OM M)				
	. ,				

MID A	Clini	riale	NIO	work

	Nalox one Challenge (NXC)	
	Taloxolo on allongo (Lixe)	Web Version: 1.0; 2.00; 01-03-
Segment (PROTSEG): B Visit number (VISNO): Challenge number (NXC_CHNO):		
Date of last XR-NTX injection: (NXXRNTDT)	(mm.Hddyyygy)	
Date of naloxone administration:(NXD OSEDT)	(mm.ldd/yyyy)	
First Dose		
1. Time of a dministration:(NXDOSTM1)	(hh:mm) (24-hour clock)	
Total dose:(NXDOSE1) Route of administration:(NXROUTE1)	(x.xx) mg	
3. Notice of administration (PARNOUTE))	1-I.V. (Intravenous) 2-I.M. (Intramuscular injection) 3-S.C. (Subcutaneous injection)	
Second Dose (if applicable)		
Note: If a second dose was administered within 5 minutes, the btal quantitys hould be entered above as a single first dose. 4. Time of administration (NXDOSTM2)	(ith:mm) (24-hour clock)	
5. Total dose:(NXDOSE2)	(x.xx) mg	
6. Route of administration: (NXROUTE2)	1-I.V. (Intravenous) 2-I.M. (Intramuscular injection) 3-S.C. (Subcutaneous injection)	
Results 7. Result of naloxone challenge: (NXRE SULT)	□ Negative □ Positive	
8. Proceed with administration of study medication? (NXA DM MED)	No Yes	
Comments:(NXCCQMM)		

Additional Selection Options for NXC Challenge number (NX C_CHNO) (key field): 1-1 2-2 3-3 4-4 5-5 6-6 7-7

Naloxone Withdrawal Symptoms (NXW)

Segment (PROTSEG): B Visit number (VISNO):

Challenge number (NXC_CHNO):

Date of	of assessment (NXWASMDT)
---------	--------------------------

(mm/dd/yyyy)

Vital Signs

Timeframe	Pulse:	Respiration Rate:	Blood Pressure: (Systolic/Dias tolic)	
Pre-injection	(NXPULSPR) (xxx)	(NXRESPPR) (xx)	(NXSYSTPR) (xxx) (NXDISTPR) / (xxx) mmHg	
10-30 minutes post-injection	(NXPULSP T) (xxx)	(NXRESPPT) (xx)	(NXSYSTPT) (XXX) (NXDISTPT) / (XXX) mmHg	

Event Grading Scale

Grade 1 Mild Transient or mild discomfort (< 48 hours), no or minimal medical intervention/therapy required, hospital zation not necessary (non prescription or single use prescription her agy may be employed to relieve symptoms, e.g., aspir infor simple headache, a cete minophen for post surgical pain)

Grade 2 Moderate Mild to moderate limitation in activity some assistance may be needed; no or minimal intervention/therapy

Grade 3 Severe Marked limitation in activity, some assistance usually required; medical intervention/ therapy required

hospitalization possible.

	Pre-injection	10 - 30 Minutes Post-injection	
Were all symptoms assessed and were none reported?	(NXNOSYPR) No Yes	(NXNOSYPT) No Yes	
Symptom	Severity of Symptom:	Maximum Severity of Symptom:	
Rhinorrhea	O-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	
Lacrimation	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	
Mydr ias is	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	
Piloerection	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	
Diaphor esis	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	
Chills	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	

Web Version: 1.0; 1.00; 01-28-14

Anxiety	(NXANXTPR)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	(NXANX TP T)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe
Yawning		0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe		0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe
Tremulousness	(NXTREMPR)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	(NXTREMPT)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe
Stomach cramps	(NXSTMCPR)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe	(NXSTMCPT)	0-Absent 1-Grade 1- Mild 2-Grade 2- Moderate 3-Grade 3- Severe

Comments: (NX WCOMM)

Additional Selection Options for NXW Challenge number (NX C_CHNO) (key field): 1-1 2-2 3-3 4-4 5-5 6-6 7-7

IDA Clinical Trials Notwork	

Segment (PROTSEG): B Visit number (VS NO): Complete this formority for females. Date of assessment (PB CASM DT) 1. Is participant continuing to use an effective method of birth control? (PBUSEBC) 2. Was a pregnancy test performed? (PBPRGTST) a. Date of pregnancy test (PBPTS TDT) b. Result of pregnancy test: (PBRE SULT) Positive results must be reported on the Confirmed Pregnancy and Outcome Form. Comments: (PBCCOMM)

Web Version: 1.0; 3.02; 12-09-14

Psychosocial Counseling Participation Log (PCL)

Segment (PROTSEG): B

Week	Did counseling occur?		If "Yes", how much: (hours/week)				
		Individual (xx)	Group (xx)	AA/NA (xx)	Other (xx)		
1	(PC1CNSL) □ No □ Yes □ Unknown	(PC 1IDHR)	(PC 1GRHR)	(PC 1A AHR)	(PC 10THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
2	(PC2CNSL) □ No □ Yes □ Unknown	(PC2IDHR)	(PC2GRHR)	(PC2A AHR)	(PC20THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
3	(PC3CNSL) □ No □ Yes □ Unknown	(PC3IDHR)	(PC3GRHR)	(PC3A AHR)	(PC30THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
4	(PC4CNSL) No Yes Unknown	(PC4IDHR)	(PC4GRHR)	(PC 4A AHR)	(PC40THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
5	(PC5CNSL) ☐ No ☐ Yes ☐ Unknown	(PCSIDHR)	(PC5GRHR)	(PC5A AHR)	(PC50THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
6	(PC6CNSL) □ No □ Yes □ Unknown	(PC&DHR)	(PC6GRHR)	(PC6A AHR)	(PC60THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
7	(PC7CNSL) No Yes Unknown	(PC7IDHR)	(PC7GRHR)	(PC7AAHR)	(PC70THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
8	(PC8CNSL) □ No □ Yes □ Unk nown	(PC8IDHR)	(PC8GRHR)	(PC8A AHR)	(PC80THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	
9	(PC9CNSL) No Yes Unknown	(PC9IDHR)	(PC9GRHR)	(PC9A AHR)	(PC90THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other	

Web Version: 1.0; 2.00; 11-15-13

10	(PC10CNSL) No	Yes Unkno	(PC10IDHR)	(PC 10 GRHR)	(PC 10AAHR)	(PC100THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
11	(PC11CNSL) No	Yes Unkno	(PC11IDHR)	(PC11GRHR)	(PC 11 AAHR)	(PC110THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
12	(PC 12 CNSL) No	Yes Unkno	(PC 12 IDHR)	(PC 12 GRHR)	(PC 12 AAHR)	(PC120THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
13	(PC13CNSL) No	Yes Unkno	(PC13IDHR)	(PC 13GRHR)	(PC 13AAHR)	(PC130THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
14	(PC14CNSL) No	Yes Unkno	(PC14IDHR)	(PC 14GRHR)	(PC 14AAHR)	(PC140THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
15	(PC15CNSL) No	Yes Unkno	(PC15IDHR)	(PC 15GRHR)	(PC 15AAHR)	(PC150THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
16	(PC16CNSL) No	Yes Unkno	(PC16IDHR)	(PC 16GRHR)	(PC 16AAHR)	(PC160THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
17	(PC 17 CNSL) No	Yes Unkno	(PC17IDHR)	(PC 17GRHR)	(PC 17AAHR)	(PC170THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
18	(PC 18CNSL) No	Yes Unkno	(PC18IDHR)	(PC 18GRHR)	(PC 18AAHR)	(PC180THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
19	(PC 19 CNSL) No	Yes Unkno	(PC19IDHR)	(PC 19GRHR)	(PC 19AAHR)	(PC190THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
20	(PC20CNSL) No	☐ Yes ☐ Unkno	(PC20IDHR)	(PC20GRHR)	(PC20AAHR)	(PC200THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
21	(PC21CNSL) No	Yes Unkno	(PC21IDHR)	(PC21GRHR)	(PC21AAHR)	(PC21 OTHR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other

22	(PC22 CNSL) No Yes Unknown	(PC221DHR)	(PC22GRHR)	(PC22AAHR)	(PC22 OTHR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
23	(PC23CNSL) □ No □ Yes □ Unknown	(PC23IDHR)	(PC23GRHR)	(PC23AAHR)	(PC230THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other
24	(PC24CNSL) No Yes Unknown	(PC24IDHR)	(PC24GRHR)	(PC24AAHR)	(PC240THR)	1-Did not want to 2-Too busy 3-Too inconvenient 4-Don't think it helps me 99-Other

Comments:(PCLCOMM)

Protocol Deviation Review (PDR)

Web Version: 1.0; 3.00; 03-17-16

Date of deviation (PDDATE): Protocol deviation number (PDSEQNUM):

Completed by Protocol Specialist:

o completion by a recessive openium on	
What section of the protocol does this deviation refer to? (PDSECTN)	
Does the report of this deviation require site staff retraining?(PDTRAIN)	No Yes
If "Yes", specify plan for retraining:(PDPLATRA)	
3. Deviation was discussed with Lead Investigative Team on:(PDDISCDT)	(mm/dd/yyyy)
4. Deviation is categorized as:(PDCATGRY)	Major Minor
5. Deviation assessment by Protocol Specialist complete: (PDPSCMP)	No Yes
Protocol Specialist reviewer:(PDPSRVID)	(initials)
Protocol Specialist comments:(PDPSCOMM)	
Completed by Protocol Monitor:	
 Corrective action for this deviation was completed and documented on-site as described:(PDACTDOC) If "No", specify reason:(PDSITESP) 	No Yes
, opos.i, rouse.i.(i 2 ei / 2 ei /	
7. Deviation was reported to the IRB as required: (PDIRBRPT)	No Yes
If "No", specify reason:(PDIRBSP)	
Preventive action plan related to this event was completed and documented on-site as described: (PDPREVNT)	No Yes
9. Review by Protocol Monitor is complete:(PDPMCMP)	No Yes
Protocol Monitor reviewer:(PDPMRVID)	(initials)
Protocol Monitor comments:(PVCOMM)	

Additional Selection Options for PDR

Protocol deviation number (PDSEQNUM) (key field):

01-1st Protocol Deviation of the day

02-2nd Protocol Deviation of the day

03-3rd Protocol Deviation of the day

04-4th Protocol Deviation of the day

05-5th Protocol Deviation of the day

06-6th Protocol Deviation of the day

07-7th Protocol Deviation of the day

08-8th Protocol Deviation of the day

09-9th Protocol Deviation of the day

10-10th Protocol Deviation of the day

NIDA Clinical Trials Network

P	Protocol Deviation (PDV)	
Date of deviation (<i>PDDATE</i>): rotocol deviation number (<i>PDSEQNUM</i>):	Web Version: 1.0; 1.0	12;04-04-17
Date deviation identified:(PDVDATE)	(mm/cld/yyyy)	
2. Deviation type: (PDTYPE)	Z01-INFORMED CONSENT PROCEDURES 01A No consent/assent obtained 01B Invalid/incomplete informed consent form 01C Unauthorized assessments and/or procedures conducted prior to obtaining informed consent 01D Non IRB approved/outdated/obsolete informed consent documents used *Additional Options Listed Below	
If 'Other', specify: (PDTYPSP)		
3. Brief description of what oc curred: (PDDES CPT)		
Brief description of the actual or expected corrective action for this event: (PDA CTION)		
5. Brief description of the plan to prevent recurrence: (PDPREVRE)		
6. Is this deviation reportable to your IRB?(PDIRBREP)	□ No □ Yes	
If "Yes", will the IRB be notified at the time of continuing review?(PDIRBCON)	No Yes	
If "Yes", date of planned submission: (PDIRBPDT) If "No", date of actual submission: (PDIRBADT)	(mm/ddl/yyy) (mm/ddl/yyy)	
Comments:(PDVCOMM)		

Additional Selection Options for PDV

Protocol deviation number (PDSE QNUM) (key field):

01-1 st Protocol Deviation of the day 02-2nd Protocol Deviation of the day 03-3rd Protocol Deviation of the day

04-4th Protocol Deviation of the day 05-5th Protocol Deviation of the day 06-6th Protocol Deviation of the day

07-7th Protocol Deviation of the day 08-8th Protocol Deviation of the day

09-9th Protocol Deviation of the day

10-10th Protocol Deviation of the day

Deviation type:

0.1E—Informed consent process not properly conducted and/or documented
0.1Z—Other (specify)

Z02-NGLUSIONEXCLUSION CRITERIA

02A--- heligible participant randomized/inclusion/exclusion criteria not met 02Z--- Other (specify) Z04-LABORATORY ASSES SMENTS

04A--- Biologic specimen not collected/processed as per protocol

04Z--- Other (specify)
Z05-STUDY PROCEDURES/ASSES SMENTS

05A--- Protocol required visit/assessment not scheduled or conducted

05B--- Study as sessments not completed followed as per protocol 05C--- Inappropriate unblinding

05Z--- Other (specify) Z06-ADVER SE EVENT 06A--- AE not reported

O68--- AE not reported
 O6C--- AE /SAE reported out of protocol specified reporting time frame
 O6D--- AE /SAE not elicited, observed and/or documented as per protocol

OEE.—Safety assessment (e.g. labs, ECG, clinical referral to care) not conducted per protocol 062.—Other (specify)

277-RANDOMIZATION PROCEDURES

07A--- Stratification error

07Z--- Other (specify)
Z08-STUDY MEDICATION MANAGEMENT

Z08-STUDY MEDICATION MANAGEMENT

088— Medication dispensed to ineligible participant

088— Medication dispensed to incorrect participant

08C— Medication dosing errors (protocol specified dose not dispensed)

08C— Participant use of protocol prohibited medication

08Z— Other (specify)
Z09-STUDY BE HAVIORAL INT ERVENTION
09A--- Study behavioral intervention was not provide d/performed as per protocol

092— Other (specify)
299-OTHER SIGNIFICANT DEVATIONS
99A—Destruction of study materials without prior authorization from sponsor
99B—Beach of Confidentiality

99Z--- Other (specify)

Physical Examination (PEX)

Segment (PROTSEG): B

isit number (VIS NO):						
Date of assessment (PEXASM	DT)					(mm/dd/yyyy)
Date of assessment (PEXASM	DT)					(mm/dd/yyyy)
					Comments	
General appearance:	3-Abn	mal normal, not clinically significant normal, clinically significant at assessed	(PEGASP)			
Skin, hair, and nails:	1-Non 2-Abn 3-Abn	mal Iormal, not clinically significant Iormal, clinically significant It assessed	(PESHNS P,			
Head and neck:	1-Norma 2-Abnor 3-Abnor 97-Not a	mal, not clinically significant mal, clinically significant	(PEHDNKS)	9)		
Ears, eyes, nose, and throat		nal, not clinically significant nal, clinically significant	(PEENTSP)			
Cardiovascular:		mal, not clinically significant mal, clinically significant	(PECARDS)	9)		
Respiratory:		mal, not clinically significant mal, clinically significant	(PERESPSI	9)		
Gastrointestinal:		mal, not clinically significant mal, clinically significant	(PEGASTSF	,,		
Extremities:		nal, not clinically significant nal, clinically significant	(PEEX TRSF))		
Lymph nodes:		mal, not clinically significant mal, clinically significant	(PEL YMP S	9)		
Musculoskeletal:	3-Abnor	al mal, not clinically significant mal, clinically significant assessed	(PEMUSCS	p)		

Web Version: 1.0; 3.01; 03-17-16

Neurological:		1-Normal 2-Abnormal, not clinically significant 3-Abnormal, clinically significant 97-Not assessed	(PENEURSP)			
Injection site assessment	(PENEUR)	1-Normal 2-Abnormal, not clinically significant 3-Abnormal, clinically significant 97-Not assessed	(PEINUSSP)			
Other (specify in comments):	(PEINUS)	Normal Abnormal, not clinically significant Abnormal, clinically significant 97-Not assessed	(PEOTHESP)			
Is the participant in good generation				□ No □ Yes		
Comments: (PEHLTHS P)	a 10 an 1, (12			No L Yes		
Comments: (PEXC OMM)						

IDA Clinical Trials Notwork	

Pregnancy		

Web Version: 1.0; 1.00; 07-26-13

Pregnancy number (PGSEQNUM):

Newborn Information

- 1. Gender: (PO1GENDR)
- 2. Gestational age at delivery:(P01GESWK)
- 3. Weight at delivery: (PO1WTLBS)
- 4. Apgar score at 1 minute:(PO1APG1M)
- 5. Apgar score at 5 minutes: (PO1APG5M)
- 6. Normal infant? (PO1NORML)

If "No", is there a congenital anomaly?(P 01 CONAN)

If "Yes", specify abnormality and contributing factors: (PO1ABNSP)

Comments:(PO1COMM)

Male Female Unknown	
(xx) Weeks (PO1GESDY) (x) Days (PO1GESUN) OR	Un know
(xx) Lbs (P01WT0Z) (xx) Oz (P01WTUNK) 0R	Un known
(xx) (P 01 1AP UK) OR Un known	
(xx) (P O1 5AP UK) OR Un known	
□ No □ Yes	
No Yes Unknown	

Additional Selection Options for PO1 Pregnancy number (PGSEQNUM) (key field): 01-1 st Pregnancy 02-2nd Pregnancy 03-3rd Pregnancy 04-4th Pregnancy

DA	Clin	Tris	ale I	Motu	work

Confirmed Pregnancy and Outcome (PRG)

Pregnancy number (PGSEQNUM):

Inform	ation	About	Pred	nancy

- 1. Date on which study staff became aware of pregnancy:(PRAWARDT)
- 2. How was the pregnancy confirmed? (select all that apply)
- a. U rin e pregnancy test result: (PRURICNF)
- b. Serum pregnancy test result (PRSERCNF)
- c. Ultra sound result:(PRULTCNF)
- d. Other: (PROTHCNF)

If "Other", specify: (PROTCNSP)

- 3. Date on which the pregnancy was confirmed: (PRCNFMDT)
- 4. Action taken with study drug: (PRACTIND)
- 5. Approximate due date:(PRAPX DDT)
- 6. Outcome of pregnancy: (PROUTCME)

If "Other", specify: (PROTCMSP)

- 7. Date of pregnancy outcome: (PROTCMDT)
- 8. Number of live births:(PRNMLNB)

If "0" live births, indicate reason:(PRRSOBSP)

Comments:(PRGC OMM)

No			
	Yes Yes		
	res Yes		
140	165		_
	(mm/dd/yyyy)		
0-None			
1-Decreased 2-Increased			
3-Temporari	ly stopped drug		
4-Permanen	tly stopped drug		
	((I.II.)	(PRDDTUNK) OR	Unknown
		77755757779	- Cinarowii
1-Vaginal de			
2-Cesarean	delivery		
	delivery e		
2-Cesarean 3-Miscarriag 4-Termination 99-Other	delivery e n		
2-Cesarean 3-Miscarriag 4-Termination 99-Other	delivery e	low	
2-Cesarean 3-Miscarriag 4-Termination 99-Other	delivery e n	llow	_
2-Cesarean 3-Miscarriag 4-Termination 99-Other	delivery e n	low	-
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0	delivery e n ptions Listed Be	low	
2-Cesarean 3-Miscarriag 4-Termination 99-Other	delivery e n ptions Listed Be	low	_
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0	delivery e n ptions Listed Be	ilow	-
2-Cesarean 3-Miscarriag 4-Terminatic 99-Other *Additional C	delivery e n ptions Listed Be	ilow	-
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0 0-0 1-1 2-2 3-3 4-4	delivery e n h ptions Listed Be		-
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0 0-0 1-1 2-2 3-3 4-4	delivery e n ptions Listed Be		
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0 0-0 1-1 2-2 3-3 4-4	delivery e n h ptions Listed Be		
2-Cesarean 3-Miscarriag 4-Terminatio 99-Other *Additional 0 0-0 1-1 2-2 3-3 4-4	delivery e n h ptions Listed Be		

Web Version: 1.0; 1.00; 07-26-13

Additional Selection Options for PRG Pregnancy number (PGSEQNUM) (key field): 01-1st Pregnancy 02-2nd Pregnancy 03-3rd Pregnancy 04-4th Pregnancy Outcome of pregnancy: 97-Unknown

37*OTKHOWII

Number of live births: 99-Other 97-Unknown

NIDA	Clinic		Motoroul
	Clinic	al Trials	
	Clinic		Network

Eur	oQoL Questionnaire (QLE)
rgment (PROTSEG): B sit number (V.S.NO):	Web Version: 1.0; 1.00; 08-30-
Date of assessment (QLEASMDT)	(mm.Hd'yyyy)
Check the ans wer that best describes your current health state today.	
. Mobility:(QLMOBL)	1-I have no problems in walking about 2-I have some problems in walking about 3-I am confined to bed
. Sel+care (QL SLFCAR)	1-I have no problems with self-care 2-I have some problems washing or dressing myself 3-I am unable to wash or dress myself
. Usual activities (e.g., work, study, hous ework, family or leisure activities):(QLACTNE)	1-I have no problems with performing my usual activities 2-I have some problems with performing my usual activities 3-I am unable to perform my usual activities
. Pain/discomfort (QLPAIN)	1-I have no pain or discomfort 2-I have moderate pain or discomfort 3-I have extreme pain or discomfort
. An xie ty/d epression :(QL AN XDEP)	1-I am not anxious or depressed 2-I am moderately anxious or depressed 3-I am extremely anxious or depressed
Use the paper EuroQol Questionnaire Thermometer to indicate how good or bad your health is currently.	
. Health state today: (QLHLTHST)	(xxx)
Comments:(QLECOMM)	
US (English) $^{\odot}$ 1998 EuroQol Group, EQ-5D $^{^{11}}$ is a trade mark of the EuroQol Group	

א חו	Clini	riale	Motu	ork.

Risk Assessment Battery (RAB)

/ ersion:		

Segment (PROTSEG): B Visit number (VIS NO):

Date of assessment (RABASMDT)		(mm/dd/yyyy)
-------------------------------	--	--------------

Read each of the following questions very carefully. As you will see, many of these questions are very personal. We understand this and have taken great care to protect the privacy of your answers. It is very important that you answer EVERY question honestly. In fact, its better not to answer a question at all than to tell us something that is not accurate or true. Some questions may not seem to have an answer that is true for you. When this happens, you should simply choose the answer that is most right. Don't spend too much time on any one question. Remember, always ask for help if you're unsure about what to do. Thankyou for your time and cooperation.

A. Past Month Drug and Alcohol Use

	Not at all	A few times	A few times eachweek	Everyday
1. In the past month, how often have you <u>injected</u> cocaine and heroin together (Speedball)?	(RASPEDBL)			
2. In the past month, how often have you injected heroin (not mixed)?	(RAHERINJ)			
3. In the past month, how often have you <u>snorted</u> heroin (not mixed)?	(RASNRTHR)			
4. In the past month, how often have you <u>smoked</u> heroin (not mixed)?	(RA SMOKHR)			
5. In the past month, how often have you injected cocaine (not mixed)?	(RACOCINU)			
6. In the past month, how often have you snorted cocaine (not mixed)?	(RASNRTCO)			
7. In the past month, how often have you <u>smoked</u> crack, rock, or free base cocaine?	(RASMOKCO)			
8. In the past month, how often have you <u>injected</u> amphetamines, methamphetamine, speed, crank, or crystal?	(RAS PDINJ)			
9. In the past month, how often have you soonted amphetamines, methamphetamine, speed, crank, or crystal?	(RASNRTSP)			
10. In the past month, how often have you smoked amphetamines, methamphetamine, speed, crank, or crystal?	(RASMOKSP)			
11. In the past month, how often have you used benzodiazepines (benzos, benzies) such as Xanax, Valium, Klonopin, or Ativan?	(RAUSEDBZ)			
12. In the past month, how often have you taken painkillers [pills such as Percodan, Percocet, Vicodin, Demerol, Dilaudid, Darvon, Darvocet, orsyrup (Codeine)]?	(RAUSEDPK)			
Which types of painkillers did you use?(RAPKSP)				
13. In the past month, how often have you injected Dilaudid?	(RADILINJ)			
14. In the past month, how often have you used acid, LSD, or other hall ucinogens?	(RAUS DLSD)			
15. In the past month, how often have you used marijuana?	(RAUSDCAN)			
16. In the past month, how often have you used beer, wine, or liquor?	(RA DR ANK)			

B. Needle Use

17. In the p	past month,	have you in jected	drugs?(RADRGINJ)
--------------	-------------	--------------------	------------------

18. In the past month, have you shared needles orworks?(RASHNDLE)

19. With how many different people did you share needles in the past month?(RANDL WNO)

20. In the past month, how often have you used a needle after some one (with or without cleaning)?(RAUSOTND)

21. In the past month, how often have others used after you (with or without cleaning)? (RANDLEOT)

□ No □ Yes

☐ No or I have not shot up in the past month ☐ Yes

0-Zero or I have not shot up in the past month

1-1 other person

2-2 or 3 different people 3-4 or more different people

0-Never or I have not shot up or shared in the past month

1-A few times (1 or 2 times)

2-About once a week (3 or 4 times)

3-More than once a week (5 or more times)

0-Never or I have not shot up or shared in the past month 1-A few times (1 or 2 times)

2-About once a week (3 or 4 times)
3-More than once a week (5 or more times)

In the past month, how often have you shared needles with someone (RAA DISND)	e you knew (or late	erfound out) had AIDS or	was positive for H	IV, the AIDS virus?	1-A few times 2-About once	ave not shot up or shared in the past month (1 or 2 times) a week (3 or 4 times) nce a week (5 or more times)	
23. In the past month, did you get your needles from any of the following:	:						
a. I have not shot up in the past month	(RANDLNOT)	No Yes					
b. From a diabetic	(RANDLDBT)	No Yes					
c. On the street	(RANDLSRT)	No Yes					
d. Drugstore	(RANDLDST)	No Yes					
e. Shooting gallery or other place where users go to shoot up	(RANDLSGY)	No Yes					
f. Needle Exchange Program ((RANDLEXC)	No Yes					
g. Other, specify:(RANDLOSP)	(RANDLOTH)	No Yes					
24. In the past month, how often have you been to a shooting gallery/hou		-			3-More than o	(1 or 2 times) a week (3 or 4 times) nce a week (5 or more times)	
25. In the past month, how often have you been to a Crack House or other			(KACKCKHS)			(1 or 2 times) a week (3 or 4 times) nce a week (5 or more times)	
26. Which statement best describes the way you cleaned your needles d	during the past mo	on th ?(<i>R AND</i> L CLN)			1-I ALWAYS 2-I ALWAYS 3-After I shoot 4-SOMETIME	not up in the past month use new needles lean my needle just BEFORE I shoot up up, I ALWAYS clean my needle iS I clean my needle, sometimes I don't outions Listed Below	
27. If you cleaned your needles and works in the past month, how did you	u clean them?						
a. I have not shot up in the past month	(RA NL NOT)	□ No □ Yes					
b. Soap and water only	(RA NL SOAF	P) No Yes					
c. Alcohol	(RA NL ALC H	f) No Yes					
d. Bleach	(RA NL BLC H	f) No Yes					
e. Boiling water	(RA NDLWTF	R) No Yes					
f. Other, specify:(RANLCOSP)	(RA NL OTH C	C) No Yes					
g. I did not clean my needles in the past month	(RA NOTCL N	V) No Yes					
h. IALWAYS used new needles in the past month	(RA ALWAYS	S) No Yes					
		Never or I have not shot up or shared in the past month	A few times (1 or 2 times)	About once a week (3 or 4 times)	More than once a week (5 or more times)		
28. In the past month, how often have you shared rinse-water?		(RA RH20SH)					
29. In the past month, how often have you shared a cooker?		(RACOKRSH)					
30. In the past month, how often have you shared cotton?		(RACTNSH)					
31. In the past morth, how often have you divided or shared drugs using one syrings (yours or someone else's) to squirt or load the drugther syringe(s) (backloading, for example)?		(RA BCKLD)		Г	П		
C. Sexual Practices							
32. How would you describe yourself?(RASEX PRF)					-	neterosexual Gayorhomosexual Bi	exual
PLEASE NOTE: For the following questions, sex means any vag	inal intercourse,	, ana linter course (in th	e butt) or oral sex	(blowjobs, for exampl	e).		

33. With how many men have you had sex in the past month? (RAS EXMEN)			0-0 1-1 2-2 or 3		
34. With how many women have you had sex in the past month? (RASEXWMN)			3-4 or m		
			0-0 1-1		
			2-2 or 3 3-4 or m		
				women/woman	
	Never	A few times (1 or 2 times)	About once a week (3 or 4 times)	More than once a week (5 or more times)	
35. In the past month, how often have you had sex so you could get drugs?	(RA SEX4DG)				
36. In the past month, how often have you given drugs to someone so you could have sex with them?	(RA DG4S EX)				
37. In the past month, how often were you paid money to have sex with someone?	(RA POSTUT)				
38. In the past month, how often did you give money to someone so you could have sex with them?	(RAPD4SEX)				
39. In the past month, how often have you had sex with someone you knew (or later found out) had AIDS or was positive for HIV, the AIDS virus?	(RASEXHIV)				
40. In the past month, how often did you use condoms when you had sex?(RASEX SFE)			0-I have	e not had sex in the past more	uth
			2-Most of 3-Some	of the time of the time of the time	
41. In the past 30 days, how many times did you have penetrative sex (vaginal oranal sex)? (RASEXPEN)				(xx)	
42. In the past 30 days, how many times did you have penetrative sex (vaginal oranal sex) without a condom	n?(RASEX UPR)			(xx)	
D. Concerns About HIV and Testing					
If you know that you are HIV positive, skip to question 46.					
43. How worried are you about getting HIV or ADS? (RAGETHIV)			0-Not at		
			1-Slight 2-Mode	rately	
			3-Consi 4-Extrer		
44. How worried are you that you may have already been exposed to the HIV or AIDS virus?(RAEXPHIV)			0-Not at	t all	
			1-Slight 2-Mode	ty	
			3-Consi	iderably	
45. How money times have you had a blood too for the ADC (1809/DATCT/IA)			4-Extrer		
45. How many times have you had a blood test for the AIDS virus (HN)?(RATSTHN)			0-Never 1-1	r	
			2-2 3-3		
			4-4 *Additio	nal Options Listed Below	
46. When we re you last tested for HIV?(RALTMHIV)				(mm) / (RALTYHIV)	(7999)
Which of these best describes the most important reason you have not been tested for HIV in the past 1.	2 months?			(mily (NAELTHIV)	V1111
47. Reason not tested for HN: (RANOTS RN)			1-You th	nink you are at a low risk for vere afraid of finding out that	-IIV infection
			3-You d	lidn't have time other reason	,
			5-No pa	articular reason	
			97-Don'	ised to answer 't know	
48. Were you ever told that you had HIV, the AIDS virus? (RA HIVYES)			□ No	Yes Inever got the	results
49. How was assessment completed?(RACMPLT)				ed directy in ePRO	
			1-In-per 2-Telep	son visit, collected on paper hone visit, collected on pape	source r source

Comments: (RA BCOM M)		

Additional Selection Options for RAB

Which statement best describes the way you cleaned your needles during the past month? 5-I NE VER clean my needle $\,$

How many times have you had a blood test for the AIDS virus (HIV)?
5-5
6-6
7-7
8-8
9-9
10-10 or more times

DA	Clin	Tris	ale I	Motu	work

The Subjective Opiate Withdrawal Scale (SOW)

(mm/dd/yyyy)

(hh:mm)

Web Version: 1.0; 1.00; 12-16-13

Segment (PROTSEG): B Visit number (VIS NO):

Date of assessment (SOWAS MDT)

Time of assessment (24-hour for mat):(S OASMTM)

Please score each of the 16 items below according to how you feel now

Symptom	Not at All	A Little	Moderately	Quite a Bit	Extremely
1. I fe el anxio us	(SOANX)				
2. I feel like y awning	(SOYAWN)				
3. I am per spiring	(SOSWEAT)				
4. My eyes are teary	(SOOUTEAR)				
5. Mynose is running	(SONOSRUN)				
6. I hav e go ose bumps	(SOGOS BUM)				
7. I am shaking	(SOSHAKE)				
8. I have hot flushes	(ѕонот)				
9. I have cold flushes	(SOCOLD)				
10. My bones and muscles ache	(SOACHE)				
11. I feel restless	(SORESTLS)				
12. I feel nause ou s	(SONAUS)				
13. I feel like vomiting	(SOVOMIT)				
14. My muscles twitch	(SOMUSTWT)				
15. I have stomach cramps	(SOSCHCMP)				
16. I feel like using now	(SOUSENOW)				

Range 0-64. Handels man, L., Cochrane, K.J., Aronson, M.J. et al. (1987)

Two New Rating Scales for Opiate Withdrawal, American Journal of Alcohol Abuse, 13, 293-308.

Comments:(SOWCOMM)

ו א חו	Clin	ic al	Tris	ıle N	Lotur.	ork

Stroop Color and Word Test - Adult Version (STR)

(mm/dd/yyyy)

Segment (PROTSEG): B			
Visit number (VIS NO):			

1. Is the participant color-blind?(STRCLRBD)
If "Yes", leave the rest of this form blank.

2. Please complete the following fields based on the results of the Stroop Task:

	Raw Score			
Word Score (W)	(STRWRAW) (xxx)			
Color Score (C)	(STRCRAW) (xxx)			
Color-Word Score (CW)	(STRCWRAW) (x xx)			

Comments:(STRCOMM)

Date of assessment (STRASMDT)

Copyright 2002 by Stoelting Co., Wheat Lane, Wood Dale, IL 60191.

☐ No	Yes		

Web Version: 1.0; 1.00; 07-22-13

	NIDA Clinical Trials Network	
	Study Termination (STT)	Web Version: 1.0; 3.01; 0.2-09-17
Segment (PROTSEG): B		Web 7 & SUII. 1.0, 3.01, 0.20317
1. Date of study completion or last attended study visit:(STTRMDT) 2. Did the participant complete the week 36 visit?(STCOMPLT) If "No", select the primary reason for study termination (STTRMRES)	(mm/dd/yyyy) No Yes 1-Participant failed to return to clinic and unable to contact 2-Participant terminated due to practical problems (no childcare, transportation, other) 3-Participant incorcerated 5-Participant terminated due to AE/SAE	
If "Participant terminated for other clinical reasons", or "Participant terminated for other reason", specify:(STTRMOSP)	*Additional Options Listed Below	
Comments:(STTCOMM)		
Investigator's Signature I have reviewed all the data recorded on all CRF pages and certify that they are accurate and complete to the best of my knowledge.		
Principal Investigator:(STPISIGN) Date:(STPISGDT)	(mm/dd/yyyy)	

Additional Selection Options for STT If "No", select the primary reason for study termination: 6-Participant terminated for other clinical reasons 7-Participant had a significant psychiatric risk (suicidal, homicidal, psychotic) 8-Participant withdraw consent 9-Participant deceased 19-Participant terminated due to protocol deviation 99-Participant terminated for other reason

Timeline Followback (T51)

TFB week start date (TFWKSTDT):

Web Version: 1.0; 1.01; 09-07-16

Day	Sunday	Monday	Tuesday	We dnes day	Thursday	Friday	Saturday
Date	(TLDATE1)	(TLDATE2)	(TLDA TE 3)	(TLDATE4)	(TLDATE5)	(TLDA TE 6)	(TLDATE7)
Have any illicit substances or cohol been used on this day?	(TLSUBAL1) No Yes	(TLSUBAL2) No Yes	(TLSUBAL3) No Yes	(TLSUBAL4) No Yes	(TLSUBAL5) No Yes	(TLSUBAL6) No Yes	(TLSUBAL7) No Yes
. Alcoholnumber of standard lrinks (xx):	(TLALCHL1)	(TLAL CHL2)	(TLAL CHL3)	(TLALCHL4)	(TLAL CHL5)	(TLALCHL6)	(TLALCHL7)
3. Can na bi no ids / Ma rij ua na:	(TLTHCR1)	(TLTHCR2)	(TLTHCR3)	(TLTHCR4)	(TLTHCR5)	(TLTHCR6)	(TLTHCR7)
	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Belov					
l. Cocaine:	(TLCOCR1) 0-00-No use	(TLC OCR2) 0-00-No use	(TLCOCR3) 0-00-No use	(TLCOCR4)	(TLC OCR 5) 0-00-No use	(TLCOCR6) 0-00-No use	(TLCOCR7) 0-00-No use
	1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below						
5. Crack:	(TLCRAKR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection "Additional Options Listed Below	(TLCRAKR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLCRAKR3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLCRAKR4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLCRAKR5) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLCRAKR6) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLCRAKR7) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
Amp heta mine-type s ti mula nts:	(TLAMPR1)	(TLAMPR2)	(TLAM PR3)	(TLAMPR4)	(TLAM PR 5)	(TLAM PR6)	(TLAMPR7)
. The contract of the contract	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection "Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
7. B upr eno rp hin e:	(TLBUPR1)	(TLBUPR2)	(TLBUPR3)	(TLBUPR4)	(TLBUPR5)	(TLBUPR6)	(TLBUPR7)
	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
B. Opioid analgesics:	(TLOPIR1)	(TLOPIR2)	(TLOPIR3)	(TLOPIR4)	(TLOPIR5)	(TLOPIR6)	(TLOPIR7)
	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Belov
3. Methadone:	(TLMTDR1)	(TLMTDR2)	(TLM TDR3)	(TLMTDR4)	(TLMTDR5)	(TLMTDR6)	(TLMTDR7)

	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below			
10. Heroin:	(TLHERR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLHERR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLHE RR.3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLHERR4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLHERR5) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLHE RR6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection "Additional Options Listed Below	(TLHERR7) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection "Additional Options Listed Below
11. Hallucinogens, including MDMA/ecstasy:	(TLMDAR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLMDAR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLMDAR3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLMDAR4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLMDA R5) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV injection *Additional Options Listed Below	(TLMDAR6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLMDAR7) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
12. Sedatives and hypnotics, excluding Benzodiaze pines:	(TLBARR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBA RR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBARR3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBARR4) 0.00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBA RR5) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV injection *Additional Options Listed Below	(TLBARR6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV injection *Additional Options Listed Below	(TLBARR7) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
13. Benzodiaæpines:	(TLBZOR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBZOR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBZOR3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBZOR4) 0.00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBZOR5) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLBZOR6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(7LBZOR7) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
14. hhalants:	(TLNHR1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLINHR2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TUIN+IR3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLINHR4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLINHRS) 0-00-No use 1-01-0-ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLINHRS) 0-00-No use 1-01-0-ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLNHR7) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
Other Drugs							
15. Other drug 1 use:	(TLOTIRI) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R5) 0-00-No use 1-01-0ral 2-02-Nasal 3-03-5moking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT1R7) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
Specify other drug 1:	(TLOTSP11)	(TLOTSP12)	(TLOTSP13)	(TLOTSP 14)	(TLOTSP15)	(TLOTSP16)	(TLOTSP 17)
16. Other drug 2 use:	(TLOT2R1) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT2R2) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT2R3) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT2R4) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT2R5) 0-00-No use 1-01-0 ral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below	(TLOT2R6) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV injection *Additional Options Listed Below	(TLOT2R7) 0-00-No use 1-01-Oral 2-02-Nasal 3-03-Smoking 4-04-Non-IV Injection *Additional Options Listed Below
Specify other drug 2:	(TLOTS P21)	(TLOTSP22)	(TLOTSP23)	(TL OTSP24)	(TLOTSP25)	(TLOTSP26)	(TLOTSP27)

Comments: (T51 COMM)

Additional Selection Options for T 51 D1 cannabinoids 5-05-W hjscton	
9999-Other	

IIDA Clinical Trials Notworl	

TLFB Assessment Period (TAP)

Segment (<i>PROTSEG</i>): B Visit number (V.S.NO):
Date of assessment (TAPA SMDT)
1. As sessment period: (TATFS TDT)
(TA TFENDT)
2. Have any illicit substances or alcohol been taken during this assessment period?(TASUBALC
Comments:(TAPCOMM)

From: (mm/dd/yyyy) T a: (mm/dd/yyyy)	(mm
T o: (mm/dd/y yyyy)	om:
	o:
□ No □ Yes	No Yes

Web Version: 1.0; 5.01; 09-13-16

	NIDA Clinical Trials Network	
	Trail Making Test (TRL)	
County (PROTOCO), D	Trail making rest (TNL)	Web Version: 1.0; 1.00; 08-14-13
Segment (PROTSEG): B Visit number (V.B.NO):		
Date of assessment (TRLASMDT)	(mm kid/yyyy)	
Record time (in seconds) required to complete each task.		
1. Part A(TRTMPRTA)	(xxx) seconds	
2. Part B:(TRTMPRTB)	(xxx) seconds	
Comments:(TRLCOMM)		

		Motor	
DA Clir	nical T		
DA CIII			

	Treatment Satisfaction (TXS)	Web Version: 1.0; 2.00; 11-12-
Segment (PROTSEG): B Visit number (VS NO):		110 10 301. I.U, 2.0., 1112
Date of assessment (TXSASMDT)	(mm.tl d/yyyy)	
How helpful do you think the medication you received was in reducing your opicid use? (TXMEDEFT)	O-Not helpful 1-A little bit helpful 2-Somewhat helpful 3-Cuite helpful 4-Very helpful	
2. How satisfied are you with your overall experience in the study?(TXSATFY)	1-Very dissatisfied 2-Dissatisfied 3-Neither satisfied nor dissatisfied 4-Satisfied 5-Very satisfied	
3. How was assessment completed?(TXCMPLT)	O-Entered directy in ePRO 1-In-person visit, collected on paper source 2-Telephone visit, collected on paper source	
Commerts:(TXSCOMM)		
	·	

	Urine	Drua	Screen	(UDS)
--	-------	------	--------	-------

Web Version: 1.0; 5.03; 09-13-16

Segment (PROTSEG):	Е
Visit number (VIS NO):	

1. Was a urine drug screen performed?(UDTEST1)

If "No", reason: (UDNORSN)

If "Other", specify: (UDNOSP1)

1st Urine Drug Screen

- 2. Date 1st urine specimen collected:(UDCOLDT)
- 3. Was the 1sturine temperature within range? (90 -100 °F) (UDTEMP1)
- 4. Was the 1 sturine specimen determined to be adulterated?(UDADULT1)
- 5. 1st Urine Drug Screen Result(s):

Drug Name (Abbreviation)	Negative	Positive	Invalid
Ben zodiaze pi ne s (B ZO):	(UDBZ01)		
Amp he tamin e (AMP):	(UDAMP1)		
Marijuana (THC):	(UDTHC1)		
Methamphetamine (MET):	(UDM ET 1)		
Opiates (2000 ng) (OP l):	(UDOPI1)		
Cocaine (COC):	(UDCOC1)		
Ecstas y (M DMA):	(UDMDA1)		
Oxy cod on e (OXY):	(UDOXY1)		
Methadone (MTD):	(UDMTD1)		
Barbiturate (BAR):	(UDBAR1)		

Opiates (30 0ng)(OPI):(UDOP1300) Bup ren orp hine (B UP):(UDBUP1)

2nd Urine Drug Screen

6. If the 1st urine specimen was determined to be adulterated, was a second specimen collected? (UDTEST2)

If "No", reason: (UDNOR SN2)

If "Other", specify: (UDNOSP2)

- 7. Was the 2nd urine temperature within range? (90 100 °F)(UDTEMP2)
- 8. Was the 2nd urine specimen determined to be adulterated? (UDADULT2)
- 9. 2nd Urine Drug Screen Result(s):

Drug Name (Abbreviation)	Negative	Positive	Invalid
Ben zod iaze pi ne s (B ZO):	(UDBZ02)		
Amphetamine (AMP):	(UDAMP2)		
Mar iju an a (THC):	(UDTHC2)		
Methamphetamine (MET):	(UDM ET2)		
Opiates (2000 ng) (OP l):	(UDOPI2)		

2-Participan	t reported being unable to provide sample t refused to provide sample
3-Study stai 99-Other	T error
	(mm kl d/yyyy)
No 🗆	Yes
No 🗆	Yes
Negative	
Negative	Positive Invalid
No 🗆	Yes
	t reported being unable to provide sample
	t refused to provide sample

□ No □ Yes

□ No □ Yes

Cocaine (COC):	(UDCOC2)	
Ecstas y (M DMA):	(UDMDA2)	
Oxy codone (OXY):	(UDOXY2)	
Methadone (MTD):	(UDMTD2)	
Bar biturate (BAR):	(UDBAR2)	

Opiates (300ng)(OPI):(UDOP2300)

Bupren orphine (B UP):(UDBUP2)

Comments:(UDSCOMM)

☐ Negative ☐ Negative			

	NIDA Clinical Trials Network	
	Visual Analog Scale (VAS)	Web Version: 1.0; 2.01;07-08-1
Segment (PROTSEG): B Visit number (VISNO):		Web Visitori, 1.0, 201, 07-001
Date of assessment (VA SASMDT)	(mm.HdVyyyy)	
1. In the past week, how much did you crave opiates? (VACRVOPI) 2. In the past 4 weeks, how much did you crave alcohd? (VACRVALC) 3. In the past 4 weeks, how much did you crave stimulants?(VACRSTM) 4. In the past 4 weeks, how much did you crave nicotine?(VACRVWIC) 5. In the past 4 weeks, on average, how many cigarettes did you smoke per day?(VANUMCIG) Comments:(VASCOMM)	(coc) (coc) (coc) (coc)	
	-	

	NIDA Clinical Trials Network	
	Vital Signs (VIS)	
Segment (PROTSEG): B fisit number (V.S.NO):		Web Version: 1.0; 3.02; 01-09-1
Date of assessment (VISA SMDT)	(mm/cld.lyyyy)	
1. Heart rate:(VIPULSE)	(xxx) BPM	
2. Blood pressure:(VIBP SYS1)	/ (VIBPDIS1) Systolic/Dias blic (mmHg)	
Comments:(VISC OM M)		

	ala Nia	
Clinic	als Ne	twork

		NIDA CIITICAI TTAIS NELWOIK	
		Norwegian VAS (VNS)	Web Version: 1.0; 1.00; 10-03-13
Segment (PROTSEG): B Visit number (VIS NO):			web version. I.u. I.u., 1003-13
Date of assessment (VNSASM D T)		(mm.lid/yyyy)	
Have you used non-prescribed opiates during the past month? (VNOPIUSE) If "Yes", which: (Check all hat apply)		□ No □ Yes	
Methadone (Dolophine):	(VNMETUSE) No Yes		
Oxycodone (Oxycontin, Percocet, Percodan, Roxycodone, others):	(VNOXYUSE) No Yes		
Hy dro cod on e (Vico din, Lo rcet, Lortab):	(VNHYCODU) ☐ No ☐ Yes		
He ro in:	(VNHERUSE) No Yes		
Non-study bupren orphine:	(VNBUPNSU) □ No □ Yes		
Hy dro morp hon e (Dil aud id):	(VNHYMORU) No Yes		
Oxymorphone (Numorphan, Opana):	(VNO YM ORU) No Yes		
Me pe rid ine (De mero I):	(VNM EPUSE) No Yes		
Codeine (Tylenol 3):	(VNCODUSE) No Yes		
Fen tany I (Duragesic trans der mal):	(VNFENUSE) No Yes		
Morphine:	(VNM ORUSE) No Yes		
When you used opiates, answer for the time you got the greatest impact 2. Indicate how much you liked the feeling you got from opiate use:(VNOPIFEL		(x00)	
3. How much would you be willing to pay for the high described in question 2 a	bove?(VNPAYHIG)	(xox)	
Comments:(VNSCOMM)			

N	IIDA Clinical Trials Network				
Weekly	y Relapse Assessment (XRP)	b Version: 1.0; 1.00; 08-14-			
gment (PROTSEG): B sit number (VISNO):	Web) version: 1.0; 1.00,06-14-			
Date of assessment (XRPASMDT)	(mm.tld/yyyy)				
Has relapse event occurred?(XRRELAPS)	□ No □ Yes				
a. If "Yes", which was the criterion for the relapse event?(XRRLPCRT)	1-Four (4) consecutive opioid use weeks (starting day 21 or later) * 2-Seven (7) consecutive days of use by self-report (starting day 21 or later) **				
* A use week is defined as any week during which a subject self-reports at least one day of use during that week, provides a urine sample positive for non-protocol opibids, or fails to provide a urine sample (e.g., missed weekly study visit). ** Self-report of opibid (i.e., heroin or non-study prescription opioids) and other substance use will be ascertained at each weekly study visit using the Time Line Follow-back for each day leading back to the previous visit.					
Comments:(XRPCOMM)					